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Abstract: Alzheimer’s disease (AD) is a complex and progressive neurodegenerative disorder. The 
available therapy is limited to the symptomatic treatment and its efficacy remains unsatisfactory. In view 
of the prevalence and expected increase in the incidence of AD, the development  of an effective therapy 
is crucial for public health. Due to the multifactorial aetiology of this disease, the multi-target-directed 
ligand (MTDL) approach is a promising method in search for new drugs for AD. This review updates in-
formation on the development of multifunctional potential anti-AD agents published within the last three years. The ma-
jority of the recently reported structures are acetylcholinesterase inhibitors, often endowed with some additional proper-
ties. These properties enrich the pharmacological profile of the compounds giving hope for not only symptomatic but also 
causal treatment of the disease. Among these advantageous properties, the most often reported are an amyloid- anti-
aggregation activity, inhibition of -secretase and monoamine oxidase, an antioxidant and metal chelating activity, NO-
releasing ability and interaction with cannabinoid, NMDA or histamine H3 receptors. The majority of novel molecules 
possess heterodimeric structures, able to interact with multiple targets by combining different pharmacophores, original or 
derived from natural products or existing therapeutics (tacrine, donepezil, galantamine, memantine). Among the described 
compounds, several seem to be promising drug candidates, while others may serve as a valuable inspiration in the search 
for new effective therapies for AD. 
Keywords: Alzheimer’s disease, antioxidants, -amyloid anti-aggregation properties, cholinesterase inhibitors, inhibitors of -
secretase, inhibitors of monoamine oxidase A/B, multi-target-directed ligands, neuroprotective properties. 
INTRODUCTION 
Alzheimer’s disease (AD), the most common form of 
dementia, is a progressive neurodegenerative brain disorder 
resulting in loss of memory and cognitive functions, often 
accompanied by behavioural disturbances like aggression 
and depression [1]. Although the disease is multifactorial 
and heterogeneous, it has certain common hallmarks, 
namely a massive loss of cholinergic neurons, deposition of 
neurofibrillary tangles and beta-amyloid (A) aggregates 
[2]. The disease is age related and it affects about 6% of the 
population over the age of 65. Worldwide, it is estimated 
that there are about 35 million people suffering from AD. 
The incidence of AD is predicted to rise significantly in the 
next three decades, as the average age of the population 
increases [3, 4]. At present, there is no efficacious treat-
ment available that allows the recovery or even slow the 
progression of the disease, therefore, effective therapeutics 
are needed. Over 20 years ago (in 1993), the first drug,  
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tacrine (Cognex®) was approved by the U.S. FDA for the 
treatment of AD (Fig. 1). As an acetylcholinesterase 
(AChE) inhibitor, it was introduced for clinical use, based 
on the cholinergic hypothesis of AD. This hypothesis as-
sumes that in AD the level of acetylcholine (ACh) is re-
duced due to the loss of the cholinergic neurons and de-
creased synthesis of ACh [5, 6]. Due to its hepatotoxicity, 
tacrine was soon withdrawn from the pharmaceutical mar-
ket, however three other AChE inhibitors were approved as 
anti-AD drugs: rivastigmine, donepezil and galantamine 
(Fig. 1). These drugs also possess additional properties, 
although their importance is unknown at present. Rivastig-
mine is able to block butyrylcholinesterase (BuChE), while 
galantamine modulates nicotinic acetylcholine receptors 
[7]. Donepezil is a moderate inhibitor of A self-
aggregation and -secretase (BACE1) responsible for the 
synthesis of A. Donepezil also interacts with sigma-1 re-
ceptors, known for their anti-amnesic activity [8]. The cur-
rent standard of AD treatment recommends combination of 
AChE inhibitors with memantine [9, 10]. Memantine is an 
N-methyl-D-aspartic acid (NMDA) receptor antagonist, 
which protects neuronal cells and reduces excitotoxicity by 
blocking pathologic stimulation of NMDA receptors (Fig. 
1). The available therapy is considered as a short-term in-
tervention only for the symptomatic treatment leading to a 
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temporary slowdown of the loss of cognitive functions 
[11]. 
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Fig. (1). Drugs approved for the treatment of AD. 
Although AD pathogenesis is complex and remains un-
clear, a large number of biological targets for potential 
therapeutics have been identified [12, 13]. The main targets 
in current AD research include: A protein, tau protein, 
receptors (cholinergic, glutamatergic, serotoninergic, do-
paminergic, noradrenergic, histaminergic), enzymes 
(AChE, BuChE, -, - and -secretase, monoamine oxidase 
A (MAO-A), monoamine oxidase B (MAO-B)). There is 
also a number of processes involved in the pathomecha-
nism of AD which are considered as promising directions 
in the search for AD treatment. The most important are 
excitotoxicity, oxidative stress, calcium and metal dy-
shomeostasis, neuroinflammation and mitochondrial dam-
age. According to Gril and Cummings [14], current thera-
peutic targets for the treatment of AD have been classified 
into two groups: symptomatic and disease-modifying. It is 
worth noting, that such classification is too simplistic, and 
some of the targets are involved in different mechanisms. 
The symptomatic therapeutic targets include mostly recep-
tors whereas the disease-modifying targets are closely con-
nected to A, tau production and neuroprotection [15, 16]. 
Over the years, extensive scientific research has focused on 
potential disease-modifying therapies for AD [17-19]. 
The role of medicinal chemistry is to design, synthesize 
and develop novel bioactive molecules, and for this purpose 
different drug discovery strategies may be applied. The drug 
discovery paradigm, “one-target, one-drug, one-disease” 
approach dominates in the pharmaceutical industry. How-
ever, during last decade, new paradigm, so called multi-
target directed ligand (MTDL), called also designed multiple 
ligands (DMLs) or multiple ligand strategy (MLS) has been 
developed as innovative approach dedicated for complex 
diseases [20-24]. It arises from an observation that some 
well-known drugs with good clinical efficacy are promiscu-
ous molecules able to interact with more than one target. On 
the other hand, it has been observed that selective ligands 
with high specificity for a single target, often lacked clinical 
efficacy. MTDL approach may be achieved either by con-
necting different molecules endowed with high potency for 
different targets or a single agent able to modulate multiple 
targets simultaneously [25-29]. Complexity of AD and a lack 
of effective treatment of the disease prompted many research 
teams to search for multiple ligands. 
Over the years, many potential multifunctional agents for 
the treatment of age-related neurological disorders have been 
developed [30-36]. The MTDLs for AD are a combination of 
pharmacophores interacting with symptomatic and/or dis-
ease-modifying targets. The selected examples of the most 
interesting or representative ligands are presented below. 
The largest group of these agents comprises dual binding site 
cholinesterase inhibitors often with additional properties 
such as A anti-aggregating activity [34-39], neuroprotective 
and antioxidant activity [40, 41], calcium channel blocking 
[42, 43], cannabinoid CB1 receptor antagonism [44], BACE-
1 inhibition [45, 46], histamine H3 receptor antagonism [47, 
48], NMDA receptor channel blocking [49, 50], serotonin 5-
HT3 receptor antagonism [51], serotonin transporter inhibi-
tion [52]. Other examples of dual-acting ligands are MAO-B 
inhibitors with iron-chelating agents [53], metal chelators 
with BACE-1 inhibitors [54], metal chelators with antioxi-
dants [55, 56] and modulators of -secretase with PPAR
activities [57]. Most of these multifunctional ligands have 
been shown to display biological activity in vitro and require 
verification in animal models. However, several compounds 
like bis(7)-tacrine [58], ladostigil [59] and memoquin [60] 
(Fig. 2) showed promising activity in vivo and in preclinical 
or even clinical studies. 
The purpose of this review is to update the most recent 
reports on the development of multifunctional agents as 
potential drug candidates for the treatment of AD. The 
topic is very attractive for both the academia and the indus-
try, therefore the number of original papers published each 
year is increasing. Moreover, several review papers have 
been presented during the last few years [61, 62] including 
our one published in November 2011 [63]. This review will 
focus on recent disclosures of multifunctional compounds 
from the medicinal chemistry point of view published 
within the last three years. Multifunctional ligands are clas-
sified based on the biological targets, then chemical leads 
and their modifications. Biological properties of these 
ligands are presented and their structure-activity relation-
ship (SAR) is discussed. 
CHOLINESTERASE INHIBITORS WITH -
AMYLOID ANTI-AGGREGATION PROPERTIES 
AChE and BuChE are enzymes involved in cholinergic 
neurotransmission through the hydrolysis of acetylcholine 
(ACh) [64]. In healthy brain tissue, AChE is the main en-
zyme responsible for acetylcholine hydrolysis, while BuChE 
plays a supportive role [65]. As AD progresses, the activity 
of AChE decreases while that of BuChE shows a progressive 
and significant increase. It was reported that BuChE is able 
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Fig. (2). Structures of selected multifunctional ligands, potential anti-Alzheimer’s drugs. 
to compensate for the lack of AChE, thus enabling continued 
regulation of cholinergic neurotransmission [66, 67]. Recent 
studies have shown that BuChE has an influence on the 
modulation of motor control, awareness, cognition and be-
haviour by regulation of acetylcholine level in the central 
nervous system (CNS) [68-70]. Additionally, cholinesterases 
display several non-classical properties associated with A
and neurofibrillary tangles, and therefore they are important 
in the pathogenesis of AD. AChE was reported to co-localize 
with A in neuritic plaques and can enhance the rate of for-
mation of A fibrils, forming stable complexes with them. 
Moreover, AChE was suggested to be a pathological chaper-
one which induces a conformational transition in A leading 
to aggregation and fibril formation [71, 72]. It is well-
established that the peripheral anionic binding site (PAS) of 
AChE is involved in these processes. Compounds which are 
able to interact with the catalytic site (CAS) and PAS of the 
enzyme, so-called dual binding site inhibitors, are potential 
inhibitors of AChE and A aggregation. Thus, cholinesterase 
inhibitors with A anti-aggregation properties are potential 
multifunctional ligands [73-75]. 
Tacrine Derivatives 
The structure of tacrine (9-amino-1,2,3,4-
tetrahydroacridine) (Fig. 1) is widely used as a pharma-
cophoric moiety in the development of MTDLs endowed 
with an inhibitory activity against cholinesterases and A
fibril formation [76]. Tang et al. [77] continued their devel-
opment of oxoisoaporphine-tacrine heterodimers based on 
the dual-site theory. Previous studies have revealed that 
oxoisoaporphine alkaloids isolated from the rhizome of Me-
nispermum dauricum and their synthetic analogues displayed 
a high inhibitory activity and good selectivity against AChE. 
The 1-azabenzanthrone fragment of these inhibitors can in-
teract with PAS [78, 79]. A new series of compounds was 
designed by linking a tacrine pharmacophore with an oxoi-
soaporphine moiety (Fig. 3). Both fragments were connected 
by an aminoalkyl tether containing a secondary amine in the 
middle and an amide bond close to the oxoisoaporphine site. 
Differences between the molecules included the type and 
length of the linker and also modifications in the tacrine unit. 
The results of Ellman’s test [80] showed that the newly syn-
thesized hybrids were EeAChE inhibitors with IC50 values in 
the nanomolar range, from 3.4 to 910 nM. SAR analysis re-
vealed that the most potent AChE inhibitors were com-
pounds with a non-modified tacrine unit. The activity of de-
rivatives with a cyclopentyl ring instead of cyclohexyl ring 
was significantly decreased (more than 100-fold), while the 
activity of analogues with a cycloheptyl ring was comparable 
or weaker. The optimal linker contained six carbon atoms 
and also included a secondary amine and a carbonyl group. 
These hybrids also displayed activity against EqBuChE with 
IC50 values ranging from 21 to 1760 nM. The A anti-
aggregating activity of the novel compounds was estimated 
in the self-induced A1-42 and the AChE-induced A1-40
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Fig. (3). Tacrine heterodimers as cholinesterase and A aggregation inhibitors. 
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thioflavin (ThT) aggregation assays [81]. All the compounds 
exhibited a high influence on self-induced A-amyloid ag-
gregation at 10 M (35.5 - 85.8%). They also had the ability 
to inhibit AChE-induced A1-40 aggregation at 100 M (60.2 
- 89.6%). In summary, among the novel series of oxoi-
soaporphine-tacrine hybrids, the most interesting hybrid is 
compound 1, which contains the tetrahydroacridine pharma-
cophore and a six atom spacer (Fig. 3). The compounds are 
more potent inhibitors of A aggregation than the reference, 
curcumin. 
Other multifunctional agents based on the structure of 
tacrine are tacrine-benzothiazole hybrids [82]. Some 
benzothiazole derivatives are able to interact with A 
peptides and have been used as Alzheimer’s brain imaging 
agents [83], while others possess anti-aggregating and 
neuroprotective properties [84, 85]. A new series of five 
hybrids, bearing two pharmacophoric groups: tacrine and a 
benzothiazole moieties connected by a different linker, 
containing an amide bond, an alkyl or arylalkyl chain was 
developed (Fig. 3). All the synthesized compounds were 
found to be EeAChE inhibitors, with IC50 values in the 
submicromolar to low micromolar range (0.34 - 1.84 M). 
SAR analysis of the tacrine-benzothiazole hybrids indicated 
that the length of the linker, its composition and geometry 
are important for their AChE inhibitory activity. All 
compounds also showed an inhibitory activity against self-
induced A1-42 aggregation at 50 M ranging from 22.3 to 
61.3% with the most active compound 2 (Fig. 3).
Donepezil-Related Compounds 
Özer et al. [86] designed a new series of compounds 
based on a donepezil structure, which were expected to in-
hibit both cholinesterase and A aggregation. This class of 
dual-acting compounds was a combination of 4-
benzylpiperidine/piperazine and a differently substituted 
benzene ring connected by an N-acylhydrazone moiety (Fig. 
4). The benzene fragment contained one or two 
methoxy/ethoxy groups. The results of Ellman’s test showed 
that these compounds were moderate and non-selective in-
hibitors of both AChE and BuChE, with IC50 values in the 
micromolar range (53.1-88.5 M for hAChE and 48.8-98.8 
M for EqBuChE, respectively). Compound 3 (Fig. 4), bear-
ing a 4-ethoxybenzyl fragment and 4-benzylpiperidine, was 
found to be the most potent hAChE inhibitor. All compounds 
were able to inhibit the aggregation of A1-40 and A1-42, in 
comparison with the reference substance - rifampicin (69 - 
90% at 100 M). 
Dual-acting compounds with cholinesterase and A ag-
gregation inhibitory activities were identified in a series of 2-
(aminoalkyl)-isoindoline-1,3-dione derivatives [87, 88]. Tar-
get compounds were designed from structural fragments 
using molecular modelling. Two pharmacophoric groups - an 
isoindoline-1,3-dione (phthalimide) fragment and an alkyl-
amine moiety - were connected by an alkyl chain (Fig. 4). 
Synthesized compounds were found to be moderate and se-
lective EeAChE inhibitors, with IC50 values ranging from 0.9 
to 19.5 M. They were also tested in the modified thioflavin 
T assay using a smaller peptide containing 11 amino acids 
instead of the whole A [89]. The most promising compound 
was 4 (Fig. 4) (EeAChE IC50 = 1.1 M), with a heptamethyl-
ene linker, which inhibits EeAChE (IC50 = 1.1 M) and A 
fibril formation in 39.4% at 80 M. 
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Fig. (4). Donepezil-related derivatives with A anti-aggregation 
activity. 
 
Benzotriazinone and Triazafluoranthenone Derivatives 
A new series of inhibitors of A aggregation and 
AChE/BuChE was identified in two groups of derivatives: 
benzo[e][1,2,4]triazin-7(1H)-ones and [1,2,4]-triazino[5,6,1-
j,k]carbazol-6-ones [90]. A quinonimine moiety presented in 
both planar triazaheterocyclic systems is a structural element 
important for blocking the A aggregation process by - 
hydrophobic and electrostatic/polar interactions [91]. De-
signed compounds possess a variety of alkylamine or arylal-
kylamine substituents attached at position C6 in benzotriazi-
none and C5 in triazafluoranthenone (Fig. 5). The majority 
of the compounds exhibited an A1-40 anti-aggregating acti-
vity with IC50 values in the micro- or submicromolar range 
(A1-40 IC50 = 0.37-65 M). In the most cases, triazafluoran-
thenone derivatives were more potent than benzotriazinones 
with the same substituent. Results of Ellman’s assay showed 
that the tested compounds were weak or moderate inhibitors 
of EeAChE and EqBuChE, however, among both groups two 
interesting multifunctional ligands were selected. Compound 
5 (Fig. 5), a benzotriazinone derivative with a diaminoalkyl 
chain and phenyl ring at the end of the linker, displayed bal-
anced biological properties: an inhibition of A1-40 aggrega-
tion with IC50 = 1.4 M and inhibition of EeAChE and 
EqBuChE with IC50 values of 1.5 M and 1.9 M, respec-
tively. Moreover, compound 5 showed A1-42 anti-
aggregating activity, which was suggested may result from 
the ability to disrupt -sheet interactions. Compound 6 (Fig. 
5), a triazafluoranthenone derivative with an octamethylene 
chain, was found to be a potent inhibitor of A1-40 aggrega-
tion with IC50 value of 1.4 M and a selective, very potent 
EqBuChE inhibitor with IC50 = 25 nM. These two leads 
(compound 5 and 6) are promising agents for further devel-
opment as potential anti-AD drugs. 
Diarylimidazole Derivatives 
Promising dual-acting diarylimidazole hybrids have re-
cently been reported [92]. The main objective of the project 
was to obtain a lead compound, as a selective and potent 
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Fig. (5). Benzotriazinones and triazafluoranthenones with AChE/BuChE inhibitory activity and A anti-aggregation activity. 
 
EqBuChE and A-aggregation inhibitor. The chemical li-
brary of nearly seven hundred (696) natural and synthetic 
compounds containing flavonoids, alkaloids, coumarins, 
chalcones, imidazoles, benzimidazoles or thiophenes was 
screened for inhibition of EqBuChE. The screening assay led 
to the selection of three hits, imidazole derivatives which 
displayed EqBuChE inhibitory activities with IC50 values in 
the range of 0.2 to 4 M. The most potent and selective Bu-
ChE inhibitor was found to be compound 7 (Fig. 6). A series 
of a following generation of imidazole derivatives was de-
veloped based on this lead and the results of molecular  
modelling. Compound 8 (Fig. 6) was an analogue of com-
pound 7 with a thienyl group and a thioethyl substituent in-
stead of a methoxy group. It was found to be the most active 
EqBuChE inhibitor (IC50 = 0.10 M). Extended biological 
studies revealed that compound 8 displays a high potency for 
inhibition of A1-40 fibril formation with an IC50 value 5.8 
M. It was proposed that due to the presence of a thiophene 
moiety, this compound participates in the binding to prefi-
brils and therefore might prevent or delay the formation of 
A assembles. 
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Fig. (6). Diarylimidazole derivatives - selective BuChE and A 
aggregation inhibitors. 
 
Isaindigotone Derivatives 
Isaindigotone (Fig. 7) is a naturally occurring alkaloid, 
the structure of which is based on a deoxyvasicinone moiety 
linked with a substituted benzylidene fragment [93]. The 
similarity of tacrine structure to deoxyvasicinone led to the 
discovery of a novel series of cholinesterase inhibitors 
among isaindigotone derivatives [94]. Continuing on from 
their previous studies, Yan et al. [95] designed and synthe-
sized a series of novel deoxyvasicinone derivatives with ad-
ditional A anti-aggregation properties. Knowing that the 
introduction of a chlorine atom at position 6 in tacrine im-
proves the activity of its analogues, they modified a deoxy-
vasicinone moiety in the same manner. The deoxyvasicinone 
fragment was connected with an amine fragment by two dif-
ferent linkers. The first group of derivatives had an N-
phenylalkanamide linker and the second had an N-
alkylbenzamide moiety, in order to enlarge their hydrogen 
bonding interaction (Fig. 7). Some of the compounds were 
modified by expanding a cyclopentane ring in a deoxyvasi-
cinone, from five to six carbon atoms, which changed the 
planarity and linearity of the pharmacophore and therefore 
enabled the observation of their interactions with cho-
linesterases, A and influence on their activity. Synthesized 
isaindigotone derivatives displayed an inhibitory activity 
against EeAChE in the nanomolar range and EqBuChE in 
the micromolar range. SAR studies revealed that more active 
and selective compounds were found to be those with a five-
membered ring in the deoxyvascinone structure. The find-
ings suggest that more planar structure was preferential for 
blocking AChE. The majority of the active compounds was 
derived from the group containing the N-phenylalkanamide 
side chain. The most potent inhibitor, selective towards 
EeAChE vs. EqBuChE, was compound 9 (Fig. 7) with IC50 = 
41.0 nM and with a selectivity ratio about 93. All the com-
pounds were tested for their ability to inhibit self-induced 
A1-40 aggregation. Their activity was between 33.96 and 
62.31% at 10 M. Compound 9 was found to be the most 
potent inhibitor. Assays performed using a circular dichro-
ism spectroscopy and electron microscopy confirmed that 
compound 9 reduces -sheet structure formation and A1-40 
fibril formation. The presented results indicate that this com-
pound is a promising multifunctional agent for further deve-
lopment. 
Chelerythrine 
Numerous multifunctional cholinesterase inhibitors have 
been discovered in plants. Naturally occurring substances 
like coumarins, flavonoids and stilbene derivatives are an 
important source of AChE inhibitors [96]. Brunhofer et al. 
[97] presented the results of their screening tests for activity 
against cholinesterases in a library containing 502 natural 
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Fig. (7). Isaindigotone derivative as dual cholinesterase and A aggregation inhibitor. 
 
and natural-based compounds. Among the tested com-
pounds, 23 were identified as cholinesterase inhibitors with 
the most promising agent, called chelerythrine (10) (Fig. 8) - 
an isoquinoline alkaloid. Chelerythrine (10) showed a mode-
rate inhibitory activity against hAChE and hBuChE with 
IC50 values in the micromolar range (hAChE IC50 = 1.54 M, 
hBuChE IC50 = 10.34 M). This compound was also a potent 
inhibitor of self-induced A1-40 aggregation (IC50 = 4.20 M) 
and showed the high activity in disaggregating test per-
formed on A1-40 aggregates with IC50 of 13.03 M. More-
over, chelerythrine (10) displayed inhibition of AChE-
induced A1-40 fibril formation at 5, 10 and 100 M with 
48.5%, 65.0% and 88.4%, respectively. 
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Fig. (8). Structure of multifunctional derivative of isoquinoline - 
chelerythrine - an inhibitor of hAChE, hBuChE and A aggrega-
tion. 
Chalcone and Coumarin Derivatives 
In a previously reported research, chalcone and coumarin 
fragments were essential for an anticholinesterase activity, 
and in some cases for A anti-aggregating properties [98, 
99]. A novel series of multifunctional compounds with the 
chalcone or coumarin moiety were developed [100]. The 
chalcone and coumarin fragments were connected with dif-
ferent amine fragments to obtain dual-acting compounds 
(Fig. 9). All the tested compounds showed activity against 
cholinesterases comparable or weaker than the reference 
compound, galantamine. The most potent EeAChE inhibitor 
was compound 11 (Fig. 9) with IC50 value of 1.76 M. De-
rivatives of chalcone exhibited higher than coumarin inhibi-
tory activity against EqBuChE with the most potent com-
pound 12 (Fig. 9) with IC50 value of 8.27 M. All the com-
pounds were tested for their ability to inhibit A fibril forma-
tion in the thioflavin T fluorescence assay. Both chalcone 
and coumarin derivatives were found to be moderate inhibi-
tors of the self-induced A aggregation (30 - 70% at 100 
M). For oligomer formation and disassembly the biotinyl-
A1-42 single-site streptavidin assay was used [101]. In the 
oligomer formation assay, coumarin derivatives exhibited 
good inhibitory properties with IC50 values in the micromo-
lar range (1 - 36 M), while chalcone derivatives were inac-
tive. Similarly, in the disassembly test only coumarin deriva-
tives were active (IC50 values in the range of 4 to 29 M). 
Compound 13 (Fig. 9) gave the best results in the oligomer 
assembly and disassembly assay. The results obtained were 
in agreement with the assay performed using atomic force 
microscopy (AFM), which confirmed that the compounds 
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Fig. (9). Multifunctional coumarin and chalcone derivatives with AChE/BuChE and A aggregation inhibitory activity. 
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acted as fibrillogenesis inhibitors. AFM also showed that in 
the case of compound 11 the formed fibrils were signifi-
cantly shorter. Among tested compounds, coumarin deriva-
tives were found to be most promising for further studies. 
HYBRIDS WITH ACHE/BUCHE AND BACE1 IN-
HIBITORY PROPERTIES 
-Amyloid is produced by the sequential proteolytic 
cleavage of the amyloid precursor protein (APP) by the as-
partyl proteases: - and -secretase. The -secretase (me-
mapsin-2, BACE1) catalyzes the first and key step in the 
production of -amyloid peptide [102]. Thus, inhibition of 
BACE1 is seen as an attractive therapeutic target for the 
treatment and prevention of AD [103]. The identification and 
cloning of this enzyme led to better understanding of its 
physiological function and to the development of -secretase 
inhibitors [104]. Recently, numerous BACE1 inhibitors have 
been discovered, moreover a few of them have been tested in 
the early stage of clinical trials [105-107]. 
Tacrine Derivatives 
4-Oxo-4H-chromene, a flavone based compound, was 
connected with a tacrine pharmacophore in the novel hete-
rodimers reported by Fernández-Bachiller et al. [108]. The 
synthesized compounds were tested for inhibition of hAChE, 
hBuChE and hBACE1, for antioxidant properties and also 
for the blood-brain barrier (BBB) penetration. The developed 
compounds contained tacrine and 4-oxo-4H-chromene con-
nected by the linkers of the different lengths (from 7 to 12 
carbon atoms). The structures of tacrine and 4-oxo-4H-
chromene were modified by an introduction of various sub-
stituents. In the tacrine unit a chlorine atom was introduced 
at positions 6, or 6 and 8. The chromene fragment was modi-
fied by the introduction of one or two methoxy and hydroxyl 
groups at positions 5, 6 or 7. The presence of a chlorine atom 
at position 6 in the tacrine moiety improved AChE inhibi-
tion, while the introduction of a second chlorine atom de-
creased the inhibitory potency against both the enzymes. The 
presence or absence of hydroxyl and methoxy groups had 
only a little influence on the inhibition of both the enzymes. 
The developed compounds showed a stronger inhibitory ac-
tivity against EqBuChE than AChE from bovine erythrocytes 
with the IC50 values ranging from 0.175 - 100 nM and 5 - 
1000 nM, respectively. The most potent compounds were 
tested against hAChE and hBuChE. In these assays com-
pound 14 (Fig. 10) displayed an excellent inhibitory activity 
against hAChE with IC50 value of 35 pM and compound 15 
(Fig. 10) against hBuChE with IC50 value of 38 pM. Eight 
compounds were evaluated as inhibitors of hBACE1 using a 
fluorescence resonance energy transfer (FRET) assay [109, 
110]. Among them, five compounds exhibited a good inhibi-
tory activity against hBACE1 with an IC50 values below 5 
M. Noteworthy is compound 16 (Fig. 10), which is a potent 
inhibitor of both cholinesterases and hBACE1 inhibitor with 
IC50 = 2.80 	M. Compound 16 was also the best antioxidant 
in this series, being 1.3-fold more potent than Trolox (a vi-
tamin E analogue used as the reference compound) in the 
oxygen radical absorbance capacity test (ORAC assay) 
[111]. All the compounds were also tested in a parallel artifi-
cial membrane permeability assay for blood-brain barrier 
(PAMPA-BBB) [112], to explore whether they are able to 
penetrate into the brain. The majority of the tested hybrids 
showed permeability values, which indicate that they would 
cross the BBB. 
Fig. (10). Tacrine-4-oxo-4H-chromene hybrids as AChE, BuChE 
and BACE1 inhibitors. 
 
Huprine Derivatives 
Muñoz-Torrero group [113] developed hybrid com-
pounds consisting of tacrine and huprine fragments con-
nected by an alkyl or alkylamine linker, as potential inhibi-
tors of AChE, BuChE and BACE1. Structural modifications 
of these hybrids included the type of a linker and substitution 
in the tacrine moiety, moreover several enantiopure huprine-
tacrine hybrids were synthesized. All the tested compounds 
exhibited an excellent or good activity towards investigated 
targets. They were potent hAChE inhibitors with IC50 values 
in the subnanomolar to low nanomolar range (0.31 - 9.09 
nM). The strongest inhibitory activity towards hAChE was 
displayed by hybrids with a six carbon atom linker. The 
elongation of the tether led to a decrease of activity, while 
the insertion of a methylamine group in the linker had a posi-
tive effect on the hAChE inhibitory activity. The new com-
pounds were moderately potent inhibitors of hBuChE with 
IC50 values ranging from 24.6 to 139 nM. Moreover, 6-
chlorotacrine-huprine hybrids showed a good inhibitory po-
tency against BACE1 with the most active compound being 
17 (Fig. 11) (hBACE1 IC50 = 4.9 	M). These multifunctional 
compounds also exhibited a good inhibitory activity towards 
hAChE-induced A1-40 aggregation at 100 	M, with the most 
active compound being 18 (Fig. 11) (IC50 = 61.3 	M). The 
compounds showed a significant inhibitory potency against 
self-induced A1-42 aggregation ranging from 28.1 to 63.7% 
at 10 	M. Interestingly, this series was also tested for inhibi-
tion of prion protein aggregation. All of the described com-
pounds showed the ability to inhibit an AChE-induced PrP-
106-126 aggregation (23 - 67% at 100 	M) with the most 
active compound being 18 (IC50 = 68.7 	M). No significant 
changes were observed for the enantiopure and racemic hete-
rodimers regarding their biological activity. Brain penetra-
tion of these hybrids was predicted in the PAMPA-BBB as-
say. Results revealed that most of huprine-tacrine hybrids are 
able to cross the BBB. 
The same research group described novel heterodimers of 
huprine containing rhein as the second fragment which can 
provide interactions within PAS [114]. Huprine and rhein 
were connected by an alkyl or arylalkyl chain of a different 
length (5 to 11carbon atoms) (Fig. 11). All the synthe-
sizedhuprine-rhein hybrids displayed an inhibitory activity 
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Fig. (11). Huprine based hybrids - hAChE, hBuChE, BACE1 and A aggregation inhibitors. 
 
towards both hAChE and hBuChE with IC50 values in the 
nanomolar range and in the submicromolar to low micromo-
lar range, respectively. Among this series, compound 19
(Fig. 11) displayed the most balanced pharmacological pro-
file with respect to all the tested biological targets. This 
compound inhibited hAChE with an IC50 of 3.60 nM and it 
was observed that its levorotatory isomer (-)19 was compa-
rably active to the racemic mixture (hAChE IC50 = 2.39 nM) 
while its optical isomer (+)19 was over 1000-fold less active. 
Regarding the BACE1 inhibitory activity, this series of com-
pounds showed a moderate potency with the most active 
compound being 19 (BACE1 IC50 = 120 nM). It is interest-
ing to note that in this case both enantiomers were stronger 
inhibitors than the racemic mixture. All the new compounds 
were potent inhibitors of AChE-induced A1-40 aggregation 
(29.2 - 52.5% at 100 
M) and self-induced A1-42 aggrega-
tion (32.4 - 43.2% at 10 
M). Huprine-rhein hybrids were 
also evaluated in the PAMPA-BBB assay to assess their 
brain permeability. The results indicated that the majority of 
the compounds could cross the BBB. Additionally, in vivo 
tests with transgenic APP-PS1 mice were performed for the 
most promising hybrid (+)19 and (-)19. The results proved 
their ability to lower the level of hippocampal total soluble 
A and to increase the level of APP in different stages of the 
AD model. Thus, this novel huprine-rhein hybrid seems to be 
an interesting multifunctional ligand for further development 
as a disease-modifying anti-AD drug. 
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Fig. (12). Multifunctional pyrimidine derivatives with AChE/BuChE, BACE1 and A inhibitory activity. 
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Pyrimidine Derivatives 
Mohamed et al. [115, 116] designed and synthesized a 
series of 2,4-disubstituted pyrimidine derivatives. These new 
multifunctional compounds contain a centrally located 
pyrimidine moiety substituted at position 2 with various cy-
cloalkylamines, and at position 4 with arylakylamines. The 
most promising multifunctional compound selected from this 
series was 20 (Fig. 12), a dual cholinesterase inhibitor (hAChE 
IC50 = 10 M, EqBuChE IC50 = 7.6 M) and hAChE-induced 
A1-40 aggregation inhibitor (30.8% at 100 M). The follow-
ing generation of pyrimidine derivatives is represented by a 
series of compounds containing a 1-benzylpiperidin-4-amine 
derived from donepezil at position 2 with a differently sub-
stituted N-benzylamine group at position 4 [117]. Synthe-
sized compounds were found to be moderate cholinesterase 
inhibitors with IC50s in the micromolar range. They were 
also able to inhibit hAChE-induced and self-induced A1-40 
aggregation. This series was also found to be BACE1 inhibi-
tors with IC50 values ranging from 0.6 M to 8.9 M and 
with the most active compound being 21 (Fig. 12). This 
compound presents an interesting multifunctional profile 
against all the tested targets. 
Benzamide Derivatives 
A new series of benzamide derivatives was designed us-
ing a structure based approach [118]. The prototype of this 
series was compound 22 with the benzamide fragment link-
ing two indole moieties (Fig. 13). Molecular modelling re-
vealed that the indole moieties (1-indole, 3-indole) interacted 
with PAS and CAS of AChE. The indole fragments were 
replaced by the other moieties i.e. quinoline, isoquinoline 
and pyrimidine which could interact with both active sites of 
AChE. Among the new hybrids, compound 23 (Fig. 13) was 
the most active hAChE inhibitor (Ki = 6.5 nM) and hBuChE 
inhibitor (Ki = 55 nM). The multifunctional compound 23 
also displayed the ability to inhibit hBACE1 and A1-42 ag-
gregation with IC50 values 85 M and 79 M, respectively. 
Compound 24 (Fig. 13), an analogue of compound 23 with a 
positively charged pyridine ring instead of quinoline, was 
found to be the most potent inhibitor of BACE1 (IC50 = 0.31 
M) with an activity against both cholinesterases in the 
nanomolar ranges (hAChE Ki = 81 nM, hBuChE Ki = 93 
nM). Compound 24 lacked A anti-aggregating activity. 
Triazole Derivatives 
A new series of tryptoline and tryptamine triazole deriva-
tives was designed and synthesized by Jiaranaikulwanitch et
al. [119] as multifunctional agents. In a previous report 
[120], the authors discovered the structure of tryptoline as 
responsible for BACE1 inhibition. In the development of 
new multifunctional ligands the tryptamine moiety was in-
troduced as a bioisostere of tryptoline. The designed struc-
tures contained triazolylmethyltryptoline and triazolyl-2-
amino-propyltryptamine connected with a differently substi-
tuted phenyl ring. The compounds were tested for inhibitory 
activity against hBACE1 and for additional activities such as 
inhibition of A aggregation, metal chelation and antioxidant 
properties. Generally, tryptamine derivatives showed a 
higher A anti-aggregation activity than tryptolines, with the 
exception of the most active compound 25 (Fig. 14) (IC50 = 
29.86 M) which was a tryptoline derivative. It was found 
that for an A anti-aggregating activity, the optimal length 
between aromatic terminals is 8-9 Å for tryptolines and 13-
14 Å for tryptamine derivatives. Tryptamine derivatives had 
significantly stronger metal chelating capability which re-
sulted from the ability of a primary amine group of tryp-
tamine to facilitate the formation of a coordination bond 
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Fig. (13). Benzamide derivatives as AChE/BuChE, BACE1 inhibitors. 
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Fig. (14). Tryptoline and tryptamine triazole derivatives - BACE1 and A aggregation inhibitors with antioxidant and metal chelating proper-
ties. 
 
between tryptamine and iron ions. Furthermore, it was 
proven that some of the compounds exhibited the antioxidant 
activity and that 3,4-dihydroxyphenyl derivatives were the 
most potent. Three compounds, 25, 26 and 27 (Fig. 14), were 
found to be multifunctional. Compound 26 showed a moder-
ate inhibitory activity against hBACE1 (IC50 = 20.75 M), an 
inhibitory effect on A1-42 fibril formation (IC50 = 83.23 M) 
and also the ability to chelate iron ions (61% at 100 M). In 
turn, compounds 25 and 27 exhibited a weaker activity 
against hBACE1 (inhibition at 25 M 21.72% and 40.03%, 
respectively), an inhibitory effect on the A fibril formation 
(25 IC50 = 29.86 M, 27 IC50 = 56.39 M) and moderate 
metal chelating properties (42.75% and 66.45% at 100 M, 
respectively). Interestingly, these two compounds showed an 
antioxidant activity in the (di(phenyl)-(2,4,6-
trinitrophenyl)iminoazanium) (DPPH) free radical scaveng-
ing assay [121] with IC50 values of 42.91 M and 92.70 M, 
respectively. Compounds 25, 26, 27 also showed a neuropro-
tective effect against the neuronal death induced by A1-42, 
comparable to that provided by curcumin. In summary, the 
tryptoline and tryptamine triazole derivatives described here 
represent an interesting multifunctional profile in several in
vitro assays. 
CHOLINESTERASE AND MAO INHIBITORS 
The therapeutic potential of monoamine oxidase inhibi-
tors (MAOIs) in the treatment of AD has been suggested due 
to their neuroprotective properties beyond their effect on 
monoaminergic neurotransmission. The neuroprotective ef-
fect of MAOIs may result not only from the increased neuro-
transmission, but also from a reduction in the formation of 
neurotoxic products. Neurotoxic substances, such as an hy-
drogen peroxide and aldehydes promote the generation of 
reactive oxygen species (ROS) [122-125]. In recent years, 
numerous multifunctional ligands with MAO inhibitory ac-
tivity have been described. 
Donepezil-Related Derivatives 
The findings reported by Bolea et al. [126] are the most 
representative. Based on their previous study [127], the 
novel hybrids were designed by combining a ben-
zylpiperidine fragment of donepezil with compound 28 (Fig. 
15), which was one of the most interesting MAOIs pre-
viously investigated by this group. Both cores were joined by 
carbon linkers of the different lengths. The length of the 
tether that connects these two main structural fragments has
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Fig. (15). Benzylpiperidine derivatives as MAO inhibitors with anti-cholinesterase activity. 
 
a relevant effect on the binding to MAO and a weak influ-
ence on the inhibition of AChE and BuChE. A three carbon 
atom spacer was found to be optimal. In their series of new 
hybrids, compound 29 (Fig. 15) was found to be the most 
potent MAO inhibitor (rMAO-A IC50 = 5.2 nM, rMAO-B 
IC50 = 43 nM) and was also found to inhibit AChE and Bu-
ChE in the submicromolar range (EeAChE IC50 = 0.35 M, 
EqBuChE IC50 = 0.46 M). The observed activity against 
BuChE is surprising, due to the fact that donepezil is a weak 
inhibitor of BuChE and compound 28 lacks activity. Com-
pound 29 also presents significant inhibitory properties 
against self-induced (32.4% at 100 M) and AChE-induced 
(47.8% at 10 M) A1-42 aggregation. Due to the promising 
preliminary results obtained from the biological evaluation, 
compound 29 was further investigated for its additional 
properties. Recent studies have demonstrated that 29 shows 
anti-apoptotic and antioxidant properties and also possesses a 
favourable blood-brain barrier permeability [128]. These 
results indicate that 29 is a potential multi-target drug candi-
date for the treatment of AD. This compound has become a 
scaffold for the novel compounds with modifications at posi-
tion 2 in the indole moiety [129]. Thus, amide, amine, ester 
and carboxylic acid groups were introduced. The most potent 
was the analogue of 29 with a propargylamine instead of an 
N-methylpropargylamine moiety and with an additional 
methyl group at the nitrogen atom of indole. This modified 
compound displays similar activities as compound 29. Fur-
thermore, their research has shown that the propargylamine 
fragment is necessary to maintain an activity against MAO in 
this group of compounds. However, a moderate activity 
against MAO-A was also displayed by compounds with an 
ester and a hydroxyl group. Among the amines, apart from 
propargylamine, morfoline is a suitable substituent, as it is 
found in moclobemide which is a selective MAO-A inhibi-
tor. Combining the N-benzylpiperidine fragment of donepe-
zil with the N-propargylamine moiety by a central pyridine 
or a 1,8-naphthyridine ring resulted in the next series of mul-
tifunctional MAO inhibitors [130]. In a series of naphthyri-
dine derivatives, compound 30 was a very potent AChE in-
hibitor (EeAChE IC50 = 37 nM) and a moderate, but selec-
tive MAO-A inhibitor (rMAO-A IC50 = 41 M) (Fig. 15). 
Compound 31, the most potent and selective MAO-A inhibi-
tor (rMAO-A IC50 = 25 M) with a weaker activity against 
acetylcholinesterase (EeAChE IC50 = 4 M) (Fig. 15), was a 
member of the pyridine series. 
Tacrine-Selegiline Hybrids 
In their continuing search for multifunctional compounds 
for treating AD Lu et al. [131] designed hybrids of tacrine 
connected by carbon spacers of different lengths with se-
legiline, a well-known inhibitor of MAO. The inhibition 
studies of hMAO-A and hMAO-B showed that these new 
compounds are effective inhibitors of both enzymes. The 
MAO inhibitory potency was related to the length of the 
linker. Compounds with a six to ten carbon linker were po-
tent MAO inhibitors with submicromolar activities, whereas 
compounds with shorter linkers displayed activities in the mi-
cromolar range. All the compounds were potent AChE and 
BuChE inhibitors (EeAChE IC50 = 14.2 - 456 nM, EqBuChE 
IC50 = 2.03 - 66.0 nM). Compound 32 (Fig. 16) with a nine 
carbon atom tether, turned out to be a potent inhibitor of 
EeAChE (IC50 = 22.6 nM) and EqBuChE (IC50 = 9.37 nM) 
and a balanced inhibitor of both monoamine oxidases 
(hMAO-A IC50 = 0.372 M, hMAO-B IC50 = 0.181 M). 
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Fig. (16). Tacrine derivatives with MAO and cholinesterase inhibitory activity. 
 
Thus, it is expected that this hybrid could improve choliner-
gic neurotransmission by AChE and BuChE inhibition and 
protect neurons by maintaining the activity of selegiline. 
Tacrine-Homoisoflavonoid Hybrids 
Sun et al. [132] also used tacrine as a pharmacophore for 
the novel homoisoflavonoid hybrids. Derivatives of homoi-
soflavonoids were chosen because of their known MAO-B 
inhibitory activity [133]. In a new series, tacrine and homoi-
soflavonoid fragments were connected using carbon spacers 
of different lengths. They also had different substituents in 
the homoisoflavonoid moiety. All the compounds were po-
tent cholinesterase inhibitors with activities in the nanomolar 
range, and were selective MAO-B inhibitors. Compound 33 
(Fig. 16) with a methoxy group at para position in a phenyl 
ring and a six carbon atom linker, provided the best results 
for cholinesterase inhibition (EeAChE IC50 = 67.9 nM, 
EqBuChE IC50 = 33.0 nM) and hMAO-B inhibition (IC50 = 
0.401 M). Moreover, the PAMPA-BBB assay indicated that 
compound 33 should be able to cross the BBB to target the 
enzymes in the CNS. 
Pyrazoline Derivatives 
The first generation of MAOIs was represented by hydra-
zine derivatives [134]. 2-Pyrazoline can be considered as a 
cyclic hydrazine moiety and this scaffold, besides a propar-
gyl moiety, is the most common scaffold in MAO inhibitors 
[135]. Mishra et al. [136] synthesized selective, reversible 
and very potent (100 times more potent than selegiline) in-
hibitors of MAO-B. These compounds were selected through 
a structure-based virtual screening. They were 3,5-diaryl 
pyrazolines substituted by anthracene at position 3 and by a 
phenyl ring with different substituents at position 5 in pyra-
zoline. The most potent was compound 34 (Fig. 17) with 3-
nitrophenyl at position 5 in pyrazoline (hMAO-A Ki = 32.16 
nM and hMAO-B Ki = 0.31 nM). In further studies, 3,5-
diaryl pyrazolines were examined against hAChE [137]. The 
majority of the molecules were found to be potent and selec-
tive hAChE inhibitors with Ki values in the nanomolar range. 
Compound 34 inhibits hAChE with Ki = 20.6 nM. The new 
pyrazolines are very interesting dual-acting compounds due 
to their balanced effect on MAO-A, MAO-B and AChE. 
CHOLINESTERASE INHIBITORS WITH ANTIOXI-
DANT PROPERTIES 
Oxidative stress is characterized by an imbalance be-
tween the production of ROS and their removal by antioxida-
tive mechanisms. Extensive evidence suggests that free radi-
cals may be involved in the pathogenesis of AD because the 
brain tissues in AD patients are exposed to oxidative stress 
during the development of the disease. ROS production is 
due to a variety of sources including mitochondrial abnor-
malities, disturbances in the level of transition metals and 
amyloid peptides themselves. Thus, antioxidant therapy in 
dementia may bring benefits, particularly in the early stage 
of AD [138, 139]. Searching for cholinesterase inhibitors 
with additional antioxidant properties is one of the trends in 
the development of an effective therapy for AD. 
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Fig. (17). Pyrazoline derivatives with MAO and AChE inhibitory 
activity. 
 
Berberine Derivatives 
The results presented by Shan et al. [140] outline a series 
of novel cholinesterase inhibitors with antioxidant activity. 
In their previous works, they developed a novel class of 9-O-
substituted berberine derivatives, which are cholinesterase 
inhibitors [141, 142]. Berberine was chosen as a scaffold 
because it inhibits AChE (IC50 = 0.374 M) and reverses the 
A-induced memory impairment. To develop a novel series 
of compounds with multi-target profile they decided to re-
place the oxygen atom in the 9-O-substituted berberine de-
rivatives with an NH group. This novel series of 9-N-
substituted berberine derivatives showed multiple activities 
including the cholinesterase and self-induced A aggregation 
inhibition, and significant antioxidant properties in the 
ORAC assay. In this series, berberine was connected with a 
differently substituted phenyl ring by carbon spacers of dif-
ferent lengths. Among the series, compound 35 (Fig. 18), 
with an ethylene linker between the berberine and ortho-
methylphenyl ring, was found to be the most active EeAChE 
inhibitor with IC50 = 27 nM. It also displayed good antioxi-
dant activity (ORAC = 4.05 eq. of Trolox) and inhibited self-
induced A1-42 aggregation with IC50 = 2.73 M. Other 
modifications of 9-O-substituted berberine derivatives re-
sulted in a new series of berberine-tiophenyl hybrids [143]. 
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Fig. (18). Multifunctional berberine derivatives with antioxidant activity. 
 
In this series, most of the hybrids demonstrated EeAChE 
inhibitory activity in the submicromolar range and a moder-
ate to good antioxidant capacity with the ORAC values of 
0.47 - 1.94 Trolox equivalents. Compound 36 performed the 
best results in the ORAC assay (1.94 eq. of Trolox) and in a 
self-induced A1-42 aggregation test (76.8% at 20 M) (Fig. 
18). It was also found to be a moderate EeAChE inhibitor. 
Tacrine Derivatives 
Tacrine was chosen as a common pharmacophore in the 
search for multifunctional ligands with the antioxidant proper-
ties. Based on their previous studies [144], Maalej et al. [145] 
developed tacrine analogues bearing a racemic 9,10,11,12-
tetrahydro-7H-benzo[7,8]chromeno[2,3-b]quinolin-8-amine 
heterocyclic structure with a differently substituted benzene 
ring at position 7 (Fig. 19, compounds 37 and 38). Among the 
series, the compounds were found to be potent and selective 
inhibitors of hAChE in the micromolar and submicromolar 
range (IC50 = 0.30 - 5.74 M). The antioxidant activity of the 
compounds was evaluated by the ORAC method. Only com-
pound 37, which has a 4-hydroxy-3-methoxyphenyl substitu-
ent, displayed an interesting antioxidant activity (1.5-fold 
more potent than Trolox). Despite the fact that compound 38 
did not display the antioxidant activity, it showed good neuro-
protective effects against the oxidative stress in cell-based 
assay (99.46% at 50 M). The oxidative stress in cells was 
induced by the mixture of oligomycin-A and rotenone which 
37 R = 4-OH, 3-OCH3
hAChE IC50 =  0.33 M
ORAC = 1.5 Trolox eq.
38 R = 3,4,5-tri-OCH3
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Fig. (19). Tacrine derivatives with the antioxidant properties. 
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blocked the mitochondrial electron transport chain. Compound 
38 displayed lower hepatotoxicity in the cell based assay than 
tacrine. The majority of the compounds were also tested in the 
PAMPA-BBB to explore whether they would be able to pene-
trate into the brain. All the tested compounds showed the per-
meability values which indicate that these molecules could 
cross the BBB by passive diffusion. 
Recent studies have shown that carbazol derivatives ex-
tracted from root bark of Clausena harmandiana have strong 
antioxidant properties [146]. Carbazol derivatives, hepta-
phylline and 7-methoxyheptaphylline, were connected with 
tacrine by a five or three carbon atom chain and reported by 
Thiratmatrakul et al. [147]. Synthesized compounds were 
found to be moderate EeAChE inhibitors in the low micro-
molar and submicromolar range, and they displayed very 
potent antioxidant activity in the ABTS (2,2’-azino-bis(3-
ethylbenzthiazoline-6-sulfonic acid) radical scavenging as-
say [148]. The ability to scavenge radicals was displayed as 
IC50 and Trolox was used as a reference (IC50 = 23.67 M). 
The compounds showed higher radical scavenging activity 
than Trolox (IC50 = 8.34 - 11.24 M). Furthermore, they 
displayed a neuroprotective effect against the oxidative stress 
induced by H2O2 in the neuroblastoma cells and against the 
toxicity induced by A1-42 peptide in C6 astroglioma cells at 
100 M. Compound 39 (Fig. 19), bearing 7-
methoxyheptaphylline and a five carbon atom spacer, was 
chosen for in vivo studies. The effect of 39 on learning and 
memory impairment was evaluated using the Morris water 
maze and Y-maze test [149]. The Morris water maze test is 
performed to evaluate hippocampal-dependent spatial learn-
ing ability which refers to long-term memory, whereas the 
Y-maze test evaluates immediate spatial working memory, a 
form of short-term memory. Memory deficits in mice were 
induced by an anti-cholinergic agent, scopolamine. Behav-
ioural studies indicated that 39 could improve both short- 
and long-term memory deficits through the enhancement of 
cholinergic signalling. The presented compounds are promis-
ing multifunctional candidates for further development. 
The results reported by Luo et al. [150] present hybrids 
of tacrine connected by an alkyl linker to benzylamine. 
Methoxy and hydroxyl groups were introduced to benzyl-
amine to investigate their influence on the antioxidant pro-
perties. The best results were provided by compounds with at 
least one hydroxyl moiety in a benzene ring. These com-
pounds were shown to be potent antioxidants in the ORAC 
assay (1.2 - 2.7 equivalents of Trolox) and EeAChE and 
EqBuChE inhibitors in the nanomolar range. The most active 
compound was found to be 40 (Fig. 20) (EeAChE IC50 = 
4.55 nM and EqBuChE IC50 = 3.41 nM), which had a hy-
droxyl group at position 4 and a methoxy group at position 3 
in the benzene ring. Compound 40 inhibited self-mediated 
A1-42 aggregation in 71% at 20 M and was 1.9-fold more 
potent than Trolox in the ORAC assay. 
Caffeic acid displays the antioxidative activity and che-
mopreventive effect against A1-42 [151]. Therefore, Chao et
al. [152] connected caffeic acid with tacrine by alkyl linkers 
with the hope of finding cholinesterase inhibitors endowed 
with the antioxidant properties. Based on their previous stud-
ies on ferulic acid - tacrine hybrids, they chose two, three 
and six carbon atom linkers. To gain selectivity towards 
EeAChE over EqBuChE they also prepared compounds with 
a 6-chlorotetrahydroacridine instead of tacrine. The most 
active compound was 41 (Fig. 20) with an IC50 of 0.3 M 
against AChE and 29.5 M against BuChE. This compound 
showed also an inhibitory effect against self-induced and 
AChE-induced A aggregation (36.2% at 20 M and 67.7% 
at 100 M, respectively). These new compounds displayed a 
DPPH radical scavenging activity comparable to that of caf-
feic acid. 
Ebselen Derivatives 
Ebselen, which is a glutathione peroxidase (GPx) mimic, 
has the antioxidant activity which results from catalyzing the 
reduction of peroxides by glutathione [153]. This and several 
other pharmacological effects of ebselen, namely an anti-
inflammatory activity and inhibition of iron-induced tau 
phosphorylation, were considered in the design of new 
MTDLs against AD combining the important pharmacopho-
res of this compound and donepezil [154]. Among a set of 15 
derivatives, the authors chose compound 42 (Fig. 21) as a 
potential lead for their further studies. This compound was 
not only a potent AChE inhibitor with an IC50 value of 42 
nM and an effective inhibitor of AChE-induced A1-40 ag-
gregation (21.4% at 100 M), but also displayed antioxidant 
effects similar to that of ebselen. Its antioxidant properties 
were evaluated in different assays. GPx-like catalytic activity 
was tested by measuring the rates of the reduction of H2O2 
by glutathione [155]. The rates were 123.5 M/min for the 
compound 42 and 121.3 M/min for ebselen. Compound 42 
showed similar or better scavenging activities than ebselen 
EeAChE IC50 =  4.55 nM
EqBuChE IC50 =  3.41 nM
self-ind. A1-42 aggr. inh. = 71% at 20 M
ORAC = 1.9 Trolox eq.
N
H
N
H
N
OH
O
40
N Cl
HN N
H
O
OH
OH
41
EeAChE IC50 =  0.3 M
EqBuChE IC50 =  29.5 M
self-ind. A1-40 aggr. inh. = 36.2% at 20 M
AChE-ind. A1-40 aggr. inh. = 67.7% at 100 M
DPPH IC50 = 4.8 M
8
 
Fig. (20). Tacrine hybrids - cholinesterase and A aggregation inhibitors with antioxidant properties. 
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Fig. (21). Donepezil-ebselen hybrid compounds - cholinesterase inhibitors with the antioxidant properties. 
 
on hydrogen peroxide and on peroxynitrite and turned out to 
be a substrate for thioredoxin reductase. Aside from the 
pharmacological properties of compound 42, its ability to 
penetrate into the CNS was tested in an in vitro blood-brain 
barrier model and the results indicated that it could reach the 
CNS. Finally, the compound did not show any acute toxicity 
and mortality in mice at doses of up to 2000 mg/kg. The 
authors further explored the idea by fusing the pharmacopho-
res of ebselen and donepezil in a slightly different manner 
(43, Fig. 21) [156]. They developed a series of 11 new com-
pounds modified mostly at the donepezil part. Generally, they 
were weaker ChEs inhibitors with IC50 values ranging from 
0.46 M to 5.66 M against EeAChE and from 1.97 M to 
more than 15 M against EqBuChE. Their GPx-like activity 
was preserved as well as their H2O2 scavenging activity. 
Indoline Derivatives 
The results reported by Yanovsky et al. [157] present de-
rivatives of indoline-3-propionic acid. Indole-3-propionic 
acid (IPA), the natural compound, was found to be a potent 
antioxidant against oxidative damage induced by -amyloid 
[158]. The further studies showed that a reduced analogue of 
IPA, indoline-3-propionic acid, was an even more potent an-
tioxidant. Thus, a series of indoline derivatives was devel-
oped. These new compounds were substituted at position 3 
with propionic acid and its ester analogues, and substituted in 
the aromatic ring with carbamate moieties at position 4, 6 or 
7. Some of the compounds were N-methylated to compare 
their activity to unsubstituted analogues. To evaluate the im-
portance of propionic acid, they synthesized derivatives un-
substituted at position 3 in the indoline. Among the series, 
almost all of the compounds were found to be moderate cho-
linesterase inhibitors with IC50 values in the micromolar and 
submicromolar range. The antioxidant scavenging ability of 
the new compounds was tested using two luminol-dependent 
chemiluminescence-inducing systems [159]. The first system 
measured the scavenging of H2O2 and OH generated by glu-
cose oxidase (GO). The second system checked the activity 
against NO released by morpholinosydnonimine (Sin1). 
Melatonin, a derivative of IPA, was used as a reference (GO 
IC50 = 95.8 M, Sin1 IC50 = 1024 M). The synthesized 
compounds were found to be more potent than melatonin in 
both tests, with IC50 in the test with GO ranging from 70 nM 
to 24 M and in the test with Sin1 ranging from 0.57 to 8.5 
M. Among the derivatives of propionic acid, compound 44 
displayed the best radical scavenging properties in both tests 
(Fig. 22). It also significantly reduced apoptosis induced by 
H2O2 in the H9c2 cardiomiocytes (58.6% at 100 nM). Among 
the derivatives without propionic acid moieties, compound 45 
was found to be the most potent antioxidant (Fig. 22). Com-
pound 45 also decreased the cell death induced by oxidative 
stress in cardiomiocytes and reduced apoptosis induced by 
serum deprivation in a primary neuronal cell culture. Serum 
deprivation induces oxidative stress in cells because of a lack 
of necessary nutrients and trophic factors. 
Lipoic Acid Derivatives 
Rosini et al. [160] presented their studies on lipocrine 
and its analogues. Lipocrine was developed in 2005 as one of 
the first multifunctional antioxidant and cholinesterase in-
hibitors [161]. Lipocrine is a hybrid of lipoic acid (a natural 
occurring antioxidant) and tacrine. In a new series of lipoic 
acid derivatives, lipoic acid was linked with fragments of 
rivastigmine and memoquin. Compound 46 (Fig. 23), which 
is a hybrid of lipoic acid and memoquin, displayed the best 
multifunctional profile (Fig. 23). It was found to be a potent 
hAChE inhibitor (IC50 = 256 nM) and a moderate hBuChE 
inhibitor (IC50 = 2.49 M). Its activity against intracellular 
ROS formation was assessed in SH-SY5Y cells after treat-
ment with tert-butyl hydroperoxide, a compound used to 
induce oxidative damage. Compound 46 showed a signifi-
cant dose-dependent inhibitory effect on ROS formation in 
concentrations of 1 to 50 M. Moreover, it did not display 
cytotoxicity in SH-SY5Y cells up to the highest concentra-
tion. These results indicate that compound 46 functions as a 
balanced antioxidant and cholinesterase inhibitor. However, 
its AChE-induced A anti-aggregation activity is poor. 
Curcumin Derivatives 
Curcumin is structurally related to ferulic and caffeic ac-
ids and like they it has chemopreventive, antioxidant and 
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Fig. (22). Carbamate derivatives of indoline with antioxidant properties and anti-cholinesterase activity. 
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Fig. (23). Lipoic acid derivatives as antioxidants and cholinesterase inhibitors. 
 
anti-inflammatory properties which could be very useful in 
the treatment of AD [162-164]. Unfortunately, its therapeutic 
application fails due to its poor pharmacokinetics. Fang L. et
al. [165] and Fang X. et al. [166] modified the structure of 
curcumin to improve its physicochemical and pharmacoki-
netic properties while preserving a neuroprotective effect. To 
achieve this goal, they kept the heptadiendione bridge chain 
and one phenolic hydroxyl group unchanged because they 
are crucial for the neuroprotective effect. At the same time, 
they replaced the methoxy group with a bulky dimethylami-
nomethyl substituent creating a steric hindrance to the hy-
droxyl group, which is the site of metabolism of curcumin 
(compound 47, Fig. 24). With the replacement of both 
methoxy groups the stability and the antioxidant activity of 
the obtained compounds increased. The most active com-
pound 48 (Fig. 24) showed a strong free radical scavenging 
activity in the DPPH assay (IC50 = 1.6 M) and towards 
galvinoxyl radicals (IC50 = 4.9 M) whereas curcumin IC50 
values in these tests were 26.5 M and >100 M, respec-
tively. Other modifications, namely the introduction of elec-
tron-withdrawing groups (-Cl and -F) and electron-donating 
groups (-OCH3) did not influence these properties to such 
extent. Compound 48 was also the most potent inhibitor of 
A self-induced aggregation among the obtained com-
pounds. Its activity, 32% of inhibition at the concentration of 
100 M in thioflavin T assay, was similar to that of the ref-
erence compound, curcumin, which was 29% at the same 
concentration. 
O
HO
O OH
O
OH HO
O OH
R
OH
N
47, R = OCH3
DPPH IC50 = 18.6 M
Galvinoxyl Radicals IC50 = 66.6 M
48, R = CH2N(CH3)2
DPPH IC50 = 1.6 M
Galvinoxyl Radicals IC50= 4.9 M
self-ind. A1-42 aggr. inh. = 32% at 100 M
Curcumin
DPPH IC50 = 26.5 M
Galvinoxyl Radicals IC50 > 100 M
self-ind. A1-42 aggr. inh. = 29% at 100 M
47, 48
 
Fig. (24). Curcumin and its dimethylaminomethyl-substituted derivatives as antioxidants. 
Recent Development of Multifunctional Agents Current Medicinal Chemistry, 2015, Vol. 22, No. 3    389 
MULTIFUNCTIONAL METAL CHELATORS 
Transition metals such as iron (Fe), copper (Cu) and zinc 
(Zn) are essential for the proper functioning of antioxidant 
systems in the cell and play an important catalytic role in 
many enzymes. In the brains of AD patients, disturbances in 
the level of biometals were noticed. Biometals are suggested 
to have two distinct roles in the pathology of AD. The pre-
sence of biometals within the amyloid deposits indicates that 
they may directly interact with A and increase its aggrega-
tion. An alternative explanation is that an imbalance in the 
levels of metals may increase production of ROS induced by 
A. Thus, the modulation of the level of these biometals in 
the brain is also a potential therapeutic strategy for treating 
AD [167-171]. Multifunctional metal chelators may block 
metal-related oxidative stress and modulate A aggregation. 
Flavonoid Derivatives 
Li et al. developed a novel series of compounds with 
metal chelating properties [172]. This series contained fla-
vonoid derivatives because of the well-established pharma-
cological properties of flavonoids. Flavonoids show the anti-
oxidant activity which depends on the ability to inhibit the 
activity of cyclooxygenase and lipoxygenase and the ability 
to chelate the transition metals [173-175]. In this new series, 
a flavonoid scaffold was connected with an amine group 
(aliphatic or the cyclic tertiary amine) using carbon spacers 
of different lengths. The most promising compound was 49
which contained a diethylamine group connected to the fla-
vonoid scaffold by a four carbon atom linker (Fig. 25). 
Compound 49 exhibited the most potent AChE activity (IC50 
= 130 nM), high selectivity for AChE, inhibition of self-
induced A1-42 aggregation at 20 M (38.95%) and a Cu2+ 
and Fe2+ chelating effect. The flavonoid pharmacophore was 
also hybridized with tacrine. The flavonoid fragment was 
connected to tacrine by a piperazine-based alkyl spacer, 
which was able to adopt the appropriate conformation to 
establish additional interactions within the enzyme. Com-
pound 50 (Fig. 25) had the most balanced multitarget profile. 
Its anti-A (A1-42 IC50 = 6.5 M) and anti-cholinesterase 
(EeAChE IC50 = 0.133 M, EqBuChE IC50 = 0.558 M) 
activity goes in association with its metal chelating effect 
[176]. 
Coumarin Derivatives 
Xie et al. [177] developed a new tacrine-coumarin hybrid 
series. Coumarin was selected due to its A anti-aggregation 
activity and its ability to interact with PAS of AChE. Both 
scaffolds were connected by a piperazine-based alkyl spacer. 
A secondary amine group of tacrine in flavonoid-tacrine hy-
brids was converted into amide moiety, which has the ability 
to chelate metal ions. Among the target molecules, com-
pound 51 (Fig. 26) showed the highest activity against 
EeAChE (IC50 = 0.092 M) and the best anti-aggregation 
properties (67.8% inhibition at 20 M). It also showed mod-
erate EqBuChE inhibition (IC50 = 0.234 M) and effective 
chelation of Cu2+ and Fe2+. 
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Fig. (25). Flavonoid derivatives as cholinesterase inhibitors with A anti-aggregating and metal chelating properties. 
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Fig. (26). Coumarin and rhein derivatives as cholinesterase inhibitors with metal chelating properties. 
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Rhein Derivatives 
Tacrine was also hybridized with rhein, which was men-
tioned above [178]. Both fragments were connected by al-
kylene linkers of different lengths to find the optimal spacer. 
From the IC50 values it appeared that the most suitable was a 
six carbon atom tether. Compound 52 (Fig. 26) was a potent 
AChE inhibitor with IC50 = 27.3 nM and a potent inhibitor of 
AChE-induced A1-40 aggregation (70.2% at 100 M). Fur-
ther studies indicated that it acts as a metal chelator. 
Indanone Derivatives 
The indanone moiety is one of the fragments of donepezil 
that influences high affinity and selectivity for AChE [179]. 
Meng et al. [180] decided to combine the indanone moiety 
with an aromatic ring via a linker with a double bond to en-
hance the affinity for PAS. Furthermore, additional double 
bonds may provide a metal chelating activity. A series of 
indanone derivatives with various amine groups substituted 
at position 6 in indanone was synthesized. In this series, 
compound 53 (Fig. 27) was the most potent EeAChE inhibi-
tor with IC50 = 1.8 nM, and a moderate EqBuChE inhibitor 
with IC50 = 9.5 M. It also displayed metal chelating activity 
towards Cu2+, Fe2+ and Zn2+. The structural analogue of 53,
with a longer spacer connecting piperidine and indanone, did 
not show chelating properties. This fact indicates that the 
distance between the nitrogen of the piperidine ring and the 
oxygen of the phenolic group played a key role for chelation. 
Huang et al. [181] also evaluated a novel series of inda-
none derivatives with inhibitory potency against MAO and 
with other multidirectional biological activities, including the 
inhibition of self-induced A aggregation, antioxidant prop-
erties and metal chelating properties. The indanone fragment 
was combined with differently substituted benzaldehydes. 
The strongest ability to inhibit self-mediated A1-42 aggrega-
tion was provided by compound 54 (Fig. 27) (80.1% at 20 
M). It also inhibits Cu2+-induced aggregation, disassembles 
the well-structured A fibrils and chelates metals. Com-
pound 54 also displays a moderate activity against hMAO-B 
(IC50 = 7.50 M) and hMAO-A (IC50 = 37.7 M). The hy-
droxyl group at position 5 in the indanone is critical to the 
MAO activity. This was confirmed by the introduction of a 
methoxy group, which resulted in the loss of the activity. 
This compound was active in the ORAC test and proved to 
be 5.6-fold more potent than Trolox. 
Rutaecarpine Derivatives 
He et al. [182] evaluated 7,8-dehydrorutaecarpine deriva-
tives as multifunctional agents. Previously, they reported that 
compounds with 7,8-dehydrorutaecarpine moiety (a carba-
zole-based structure) were potent AChE inhibitors [183]. 
Furthermore, carbazole derivatives were reported as A ag-
gregation inhibitors with the free-radical scavenging effect 
[184]. Thus, a series of new 3-aminoalkanamido-substituted 
7,8-dehydrorutaecarpine derivatives was investigated for 
their multi-activity. The obtained compounds were demon-
strated to be very potent acetylcholinesterase inhibitors with 
the most active compound being 55 (Fig. 28) (EeAChE IC50
= 0.6 nM). Compound 55 also inhibited self-induced 
(45.9%) and AChE-induced (90.6%) A1-42 aggregation at 25 
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Fig. (27). Indanone derivatives as cholinesterase and monoamine oxidase inhibitors with metal chelating properties. 
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Fig. (28). Rutaecarpine derivative as a multifunctional metal chelator. 
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M. This lead compound chelates metals and has better anti-
oxidant properties than Trolox (ORAC at 1 M = 1.8). 
Resveratrol Derivatives 
In recent years, resveratrol (3,5,4’-trihydroxystilbene) has 
been extensively investigated as a cardioprotective, antican-
cer and anti-aging compound [185-187]. Recently, resvera-
trol-based compounds were found to have a strong anti-
aggregation and antioxidant activity [188, 189]. In a novel 
series of stilbene derivatives, compound 56 was found to be 
an inhibitor of self-induced aggregation of A1-42 (71.65% at 
20 M) with antioxidant activity (4.12 of Trolox eq. at 1 
M) [190]. As a continuation of this study, Lu et al. [191] 
developed a series of compounds with a stilbene fragment 
combined with differently substituted benzylamine moieties. 
The most promising of them, compound 57, was a potent 
inhibitor of self-induced A aggregation (79.50% at 20 M) 
with antioxidant properties (4.72 of Trolox eq. at 1 M) (Fig. 
29). Moreover, compound 57 chelates metals and inhibits 
Cu(II)-induced A aggregation (94.23% at 20 M). It also 
shows inhibitory activity towards cholinesterases and mono-
amine oxidases in the micromolar range (EeAChE IC50 = 
6.27 M and EqBuChE IC50 = 21.25 M, hMAO-A IC50 = 
7.08 M, hMAO-A IC50 = 14.09 M) (Fig. 29). 
Li et al. reported small molecules bearing the main fea-
tures of resveratrol and clioquinol [192]. They obtained imine 
resveratrol analogues with differently substituted hydroxyl 
groups as bifunctional compounds with a metal chelating and 
anti-aggregation activity. The most active compounds were 
also examined for their antioxidant and neuroprotective prop-
erties. Among the target compounds, 58 (Fig. 29) was the 
most interesting. It was an inhibitor of A self-aggregation 
(64.6% at 20 M) with neuroprotective activity better than 
resveratrol and it reduced Cu2+-induced A aggregation. 
NO-RELEASING COMPOUNDS 
Being involved in a variety of physiological and patho-
physiological processes, nitric oxide (NO) is regarded as a 
potential tool in the pharmacotherapy of many disorders, 
including dementia. NO-releasing drugs may be especially 
beneficial for the treatment of AD due to its role in the regu-
lation of the cerebral circulation and inflammatory reactions 
[193, 194]. 
Tacrine-Ferulic Acid Hybrids 
In ours previous review paper [63], we described tacrine-
ferulic acid hybrids (Fig. 30, compound 59) reported by Fang 
et al. [195]. Aside from their AChE and BuChE inhibitory 
activities, they displayed moderate to good antioxidant activ-
ity in the ORAC assay. Simultaneously, the same group de-
signed and synthesized a series of tacrine hybrids with the 
NO-donating nitrate and diazeniumdiolate moieties [196]. 
The developed compounds (Fig. 30, compound 60) displayed 
a cholinesterase inhibitory potency in the nanomolar range 
and a moderate blood vessel relaxant activity. In the behav-
ioural studies they significantly improved the scopolamine-
induced cognition impairment in rats. In contrary to tacrine, 
the new derivatives did not cause a serious hepatotoxicity 
[197]. Lately, the group combined those two ideas and pre-
sented tacrine - ferulic acid - NO donor trihybrids (Fig. 30, 
compound 61) [198]. All the compounds were potent cholin-
esterase inhibitors with IC50 values ranging from 3.6 nM to 
44.3 nM against EeAChE and 1.0 nM to 24.9 nM against 
EqBuChE. The ability of these compounds to release 
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DPPH scavening act. = 14.1 M
 
Fig. (29). Resveratrol derivatives as metal-chelating agents with additional biological properties. 
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Fig. (30). Tacrine-ferulic acid-NO-donor trihybrid and its precursors. 
 
nitric oxide was tested in the Griess reaction [199]. For the 
most active compound 61 the amount of NO produced in the 
reaction (0.31 g/mL) was similar to that produced by 
isosorbide dinitrate (0.38 g/mL), which was used as a posi-
tive control in this test. Production of the nitrite positively 
correlated with the vascular relaxation activity of the com-
pounds, which was the highest for 61 (EC50 = 34.3 M). 
Compound 61 was subjected to the passive avoidance test in 
the scopolamine-induced cognition impairment animal 
model. It significantly decreased the number of errors made 
by mice in the test as well as reduced the transfer latency 
time, indicating beneficial effects for the short-term learning 
ability and improving memory impairment. Even though the 
described compounds did not show the expected antioxidant 
activity, their cholinesterase inhibitory activity, NO-releasing 
ability and vasorelaxant effects contributed to significant 
cognition improving activity. Additionally, compound 61 
was much safer in terms of hepatotoxicity than tacrine. 
Tacrine-Flurbiprofen Hybrids 
Encouraged by the positive results associated with the in-
troduction of NO-donor group, Chen et al. [200, 201] conju-
gated a nitrate group with the previously obtained tacrine-
flurbiprofen hybrid compounds [202]. Derivatives with short 
linkers (two to four carbon atoms) connecting tacrine with 
flurbiprofen displayed a comparable or higher than tacrine 
EqBuChE inhibitory activity (IC50 = 3.9 nM - 13.9 nM). The 
majority of the compounds with longer linkers (six or eight 
carbon atoms) were more potent inhibitors of both EeAChE 
and EqBuChE (IC50 = 9.1 - 225.6 nM; IC50 = 0.6 - 3.7 nM 
respectively) than tacrine. All the trihybrid compounds re-
leased NO in amounts comparable to isosorbide mononitrate 
(0.209 - 0.565 g/mL vs. 0.412 g/mL), as shown in the 
Griess reaction. To evaluate the pharmacological effect re-
sulting from this feature, the selected compounds were tested 
in ex vivo isolated organs (coronary arteries from rats) using 
the vascular relaxation assay. In this study, a moderate 
vasorelaxation effect (21.9% - 31.3%) was observed, which 
might result from NO generation. In the passive avoidance 
test, with the scopolamine-induced impaired mice, com-
pound 61 and its NO-releasing analogue 62 (Fig. 31) proved 
to improve memory impairments, although it seems that this 
activity was not dependent on the presence of the nitrate 
group. Finally, compound 62 displayed much lower hepato-
toxicity than tacrine and compound 61, indicating the hepa-
toprotective role of NO. 
Dibenzofurane Derivatives 
NO releasing organic nitrate was also incorporated into 
the dibenzofurane and carbazole derivatives reported by 
Fang et al. [203]. Considering previous studies and the X-ray 
structure of galantamine co-crystalized with AChE [204], the 
authors concluded that the aromatic moiety (i.e., the benzene 
ring) and the nitrogen atom create the crucial interactions 
responsible for the inhibitory activity of galantamine. There-
fore, they designed compounds with a simplified structure of 
galantamine using dibenzofuran/carbazole as a backbone. 
The molecular modelling studies showed that the analogues 
with the azepane ring opened overlap with galantamine and 
they could effectively block the catalytic site of AChE. This 
hypothesis was confirmed in in vitro tests where the majority 
of the new compounds retained AChE inhibitory activity, 
and two of them were more potent than galantamine. The 
most active were the analogues with a nitric oxide donor 
attached to the backbone on a flexible aliphatic chain (i.e., 
compound 63, EeAChE IC50 = 0.18 M) (Fig. 32). Unex-
pectedly, their NO-releasing activity was rather poor (4.8 - 
6.1% of NO released from the nitrate). Compound 63 dis-
played a moderate A-aggregation inhibitory activity (25% 
at 100 M) in the thioflavin T assay but also a dose-
dependent neuroprotective effect against A-induced toxic-
ity. Most importantly, compound 63 showed a significant 
improving effect on spatial memory in rats with scopola-
mine-induced cognition impairment. 
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Fig. (31). Tacrine-flurbiprofen hybrid compound and its NO-releasing analogue. 
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Fig. (32). Galantamine and its simplified analogue with NO-releasing nitrate group. 
 
MULTIFINCTIONAL COMPOUNDS WITH NEURO-
PROTECTIVE PROPERTIES 
As previously stated, neurodegeneration is characterized 
by a progressive loss of the structure and function of neu-
rons. The purpose of neuroprotection is to counteract this 
process by targeting the most common mechanisms leading 
to it, like oxidative stress, mitochondrial dysfunction, excito-
toxicity, inflammatory changes, iron accumulation, and pro-
tein aggregation. 
Aminothiazol Derivatives 
The neuroprotective and anti-inflammatory properties 
of aminothiazoles [205] were the basis for Wang et al. 
[206] in designing a series of new potential multifunctional 
drugs for AD. The structures comprised tacrine and para-
substituted 4-phenyl-2-aminothiazole moieties connected 
by various linkers. The linkers differed in the length (6 - 11 
atoms) and structure, including an alkyl chain and succi-
namide or glycinamide fragments. An inhibitory activity 
against AChE, BuChE and A-aggregation was reported 
for these compounds as well as a calcium overload block-
ade effect. The most potent inhibitor of EeAChE was com-
pound 64 (Fig. 33) with its pIC50 = 7.14, and which also 
displayed the most significant Ca2+ overload blockade ef-
fect. Unfortunately, its anti-aggregation activity was quite 
low (35.8% at 20 M) compared to other compounds in the 
group. Compound 65 (Fig. 33) deserves attention with its 
pIC50 = 6.98 against EeAChE and with the lowest pIC50 = 
10.35 against EqBuChE. A self-aggregation was affected 
the most by compound 66 (Fig. 33) - 72% at the concentra-
tion of 20 M (57% for propidium iodide). 
Aminophenothiazine Derivatives 
As a continuation of their previous project Gonzalez-
Muñoz et al. [207] described a group of analogues of N-
acylaminephenothiazines modified within the amine group. 
They developed a series of selective BuChE inhibitors with 
IC50 values in the range from 0.4 M to 7.1 M. According 
to the PAMPA-BBB assay, the compounds could cross the 
BBB by passive diffusion. Several compounds displayed 
neuroprotective activity as shown in two toxicity models on 
human neuroblastoma cell line SH-SY5Y. The first one was 
a model using hydrogen peroxide, which generates exoge-
nous free radicals, the other one uses the combination of 
rotenone and oligomycin A for the induction of mitochon-
drial ROS. Compound 67 (Fig. 34) protected the cells from 
the damage induced by H2O2 in a dose-dependent manner 
(54.6% at 1 M, 57.7% at 3 M, 79.9% at 10 M) and it was 
a moderate free-radical scavenger in rotenone and oligomy-
cin A assay (14.7% of free radical capture vs. 27.8% for 
Trolox). Compound 67 was evaluated in additional assays. It 
displayed neuroprotective activity against A1-42 induced 
cytotoxicity (91.3% at 0.3 M) and against okadaic acid 
(28.3% at 0.3 M) - a toxin which induces tau phosphoryla-
tion and aggregation into neurofibrillary tangles [208]. The 
compound had also a neuroprotective effect in calcium over-
load assay (44.5% at 1 M). 
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Fig. (33). 4-Phenyl-2-aminothiazole-tacrine hybrids - cholinesterase and A aggregation inhibitors with Ca2+ overload blocking activity. 
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Fig. (34). N-acylamiophenothiazine derivative with the neuropro-
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Cystamine-Tacrine Dimer 
A novel multipotent anti-AD agent was designed by link-
ing two tacrine moieties via cystamine (2,2'-
disulfanediyldiethanamine) [209]. Cystamine is known for 
its antioxidant, cytoprotective and neuroprotective properties 
[210]. The obtained cystamine-tacrine dimer 68 (Fig. 35) is a 
structural analogue of bis(7)-tacrine with a disulfide bridge. 
Compound 68 displayed an inhibitory activity against both 
cholinesterases in the nanomolar range (hAChE IC50 = 5.04 
nM, hBuChE IC50 = 4.23 nM) and inhibitory properties in 
the self-induced A aggregation assay with IC50 = 24.2 M 
and in the AChE-induced A aggregation test (52% at 100 
M). Its neuroprotective effect against oxidative stress in-
duced by H2O2 was tested on SH-SY5Y cell line. A complete 
protection in this assay was observed at 0.5 M concentra-
tion. A study of a mechanism of neuroprotection revealed 
that compound 68 acts by activating two anti-apoptotic 
kinase pathways (kinase 1 and 2, and Akt/protein kinase B). 
NMDA RECEPTOR ANTAGONISTS 
A combination of the AChE inhibitor and N-methyl-D-
aspartate receptor (NMDAR) antagonist (memantine) is now 
a standard treatment of AD. Memantine has a neuroprotec-
tive effect resulting from the inhibition of an excessive cal-
cium influx induced by chronic overstimulation of the 
NMDA receptor. Simoni et al. [211] reported a series of 
compounds - chimeras of galantamine and memantine con-
nected via different linkers. AChE inhibitory activity of the 
compounds was dependent on the interactions with both 
CAS and PAS of the enzyme, therefore the length and the 
kind of the linker was crucial. The most favourable were six 
to eight-methylene spacers connecting the nitrogen of galan-
tamine and the nitrogen of memantine. The most active 
compound with IC50 of 0.52 nM had an additional methyl 
group at the nitrogen atom of memantine. Unfortunately, this 
modification had a detrimental effect on the affinity for 
NMDAR. None of the obtained compounds was as potent 
NMDAR antagonists as memantine (Ki = 1.16 M) but a few 
of them had comparable Ki values. The most interesting 
compound with a balanced activity against both targets was 
compound 69 (Fig. 36) called memagal, which additionally 
hAChE IC50 = 5.04 M
hBuChE IC50 = 4.23 M
self-ind. A1-42 aggr. inh. IC50 = 24.2 M
AChE-ind. A1-42 aggr. inh. = 52.6% at 100 M
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Fig. (35). Cystamine-tacrine dimer. 
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Fig. (36). Memagal - a chimera derivative of galantamine and 
memantine. 
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was proven to inhibit NMDA-induced neurotoxicity (IC50 = 
0.28 nM) in a cell-based assay. 
Novel multifunctional bis--carboline derivatives en-
dowed with a cholinesterase inhibitory activity, A anti-
aggregating properties and a neuroprotective effect caused 
by NMDAR antagonism were reported by Rossini et al.
[212]. These compounds have been designed as latrepirdine-
based dimers. Latrepirdine (Dimebon) was used as the anti-
histamine drug and it has been investigated as a potential 
anti-AD agent due to its inhibitory activity towards BuChE, 
AChE and NMDAR [213]. New compounds contained two 
-carboline fragments of latrepirdine connected by different 
linkers. Among syntehesized derivatives the most promising 
was compound 70 (Fig. 37), which displayed an interesting 
multifunctional profile. It was a non-selective cholinesterase 
inhibitor with a moderate activity against hAChE (IC50 = 
0.692 M) and hBuChE (IC50 = 0.737 M) and it inhibited 
A1-42 self-aggregation (71% at 50 M). Compound 70 acted 
as NMDAR antagonist (IC50 = 12.6 M at -100 mV) at re-
combinant NMDARs but it was less potent than memantine 
(IC50 = 0.71 M at -100 mV). Moreover, compound 70
showed neuroprotective effect in a low-serum cell stress 
model [214] by enhancement of the survival of cortical neu-
rons at 100 nM. 
CANNABINOID RECEPTOR LIGANDS WITH CHO-
LINESTERASE INHIBITORY ACTIVITY 
The cannabinoid system has recently been gaining more 
attention due to its involvement in anti-inflammatory, neuro-
protective and anti-amnesic actions [215, 216]. 
Benzofuran Derivatives 
Rizzo et al. [217] reported a series of novel compounds 
endowed with activity towards cannabinoid receptors. The 
authors assumed possible interactions with the receptors 
based on the structural similarity of the newly obtained com-
pounds to the high affinity CB1 antagonist/inverse agonist 
(LY320135) (Fig. 38), which is built on a benzofuran scaf-
fold. The work presented the optimization of compound 71
(Fig. 38), which was reported as an MTD lead with AChE 
inhibitory activity, A anti-aggregation properties and neu-
roprotective effect in SH-SY5Y cells. Major modifications 
include the length and the position of the linker connecting 
2-arylbenzofuran and N-methyl-N-benzylamine and the sub-
stituent at position 3 of the benzofuran scaffold. The influ-
ence of these modifications on the inhibitory activity against 
AChE and BuChE, A fibril formation and neuroprotective 
activity was verified. The major improvement was achieved 
in terms of cholinesterase inhibition. Changing the position 
of the heptyloxy-N-methyl-N-benzylamine substituent from 
para to meta resulted in the development of compound 72
(Fig. 38), which was the most active inhibitor of hAChE in 
the series and 180-fold more potent than the parent com-
pound 71 (IC50 = 0.24 M vs. 40.7 M). Regarding A fibril 
formation compound 73 (Fig. 38), an analogue of 71 lacking 
the substituent at position 3 of the benzofuran was the most 
active (IC50 = 3.9 M). The bulkier the substituent at this 
position, the worse the activity. Compound 72 as well as 
derivatives with a 1-naphthyl or 3-methoxy substituent in the 
benzofuran moiety retained the activity of compound 71,
whereas the rest of the series were only weak inhibitors of -
amyloid aggregation. Among the A fibril formation inhibi-
tors, compounds 71 and 72 counteracted neurotoxicity in-
duced by A25-35 by inhibiting peptide-induced ROS forma-
tion and preventing the interaction of the A25-35 peptide 
with the cell membrane of SH-SY5Y cells. All the intro-
duced modifications adversely affected the affinity for CB1 
receptors compared with compound 71 (Ki value of 0.32 
M). Compounds of the para series with amino moieties on 
the benzoyl group showed weak affinities for CB1 receptors 
(Ki = 0.55 - 2.57 M) and CB2 receptors (Ki = 0.58 - 1.18 
M). Functional studies of these compounds were not con-
ducted. 
Indazole Derivatves 
Gonzáles-Naranjo et al. [218] found that some of the in-
dole-based cannabinoid agonists such as JWH-015 (Fig. 39)
inhibit AChE in Ellman’s test. This discovery prompted 
them to search for new multi-target directed ligands, CB2 
agonists with cholinesterase inhibitory activity. They chose 
an indazole scaffold as an indole bioisostere and applied 
structural modifications at positions 1, 3 and 5 according to 
the molecular modelling studies. Most of the compounds 
obtained showed micromolar affinities for cannabinoid re-
ceptors, some of them being selective towards CB2 receptor 
and three of them (74, 75, 76) (Fig. 39) proved to be CB2 
receptor agonists. Compounds 74, 75 and 76 were also 
among the most potent selective BuChE inhibitors in this 
group and exhibited moderate antioxidant properties in the 
ORAC test. Therefore, these compounds were identified as 
the most interesting for further investigation.  
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Fig. (37). Latrepirdine-based bivalent ligand with anti-cholinesterase, A anti-aggregation activity and neuroprotective effect. 
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Fig. (38). LY320135 - CB1 receptor antagonist and MTDLs against AD, targeting AChE, BuChE, amyloid- formation and cannabinoid 
receptors. 
 
 
Fig. (39). Indole-based CB2 receptor agonist JWH-015 and inda-
zole-based compounds CB2 receptor agonists with BuChE inhibi-
tory activity and antioxidant properties. 
 
DUAL-ACTING COMPOUNDS TARGETING HIS-
TAMINERGIC SYSTEM 
The histamine H3 receptor (H3R) belongs to the class of 
G protein-coupled receptors (GPSRs), and as a presynaptic 
autoreceptor in the brain, inhibits the release of histamine 
and is involved in the modulation of the release of other neu-
rotransmitters. In the CNS, the histamine H3 receptors are 
localized mainly in the regions involved in important physio-
logical processes including cognition, agitation, anxiety, 
pain, food intake and body temperature regulation [219-221]. 
H3 antagonists/inverse agonists have been reported to im-
prove cognitive function, spatial orientation, attention, mem-
ory and learning in a variety of in vivo models [222-224]. 
The fusion of AChE inhibitors and histamine H3 receptor 
antagonists in a single molecule might improve cognitive 
functions in AD. 
A series of hH3 receptor antagonists with AChE/BuChE 
inhibitory activity has been recently reported [225]. Non-
imidazole diether derivatives exhibited a good affinity for 
cloned human histamine H3 receptors (Ki values in the range 
of 3 to 51 nM). Most of the compounds displayed a moderate 
or weak EeAChE inhibitory activity and moderate EqBuChE 
inhibitory activity. Regarding AChE/BuChE activity vs. hH3 
receptor affinity, compounds with the highest hH3R potency 
also showed the highest anti-cholinesterase activity. Two of 
the most interesting multifunctional compounds (77 and 78) 
(Fig. 40) displayed high affinity for hH3R (77 Ki = 3.48 nM, 
78 Ki = 7.74 nM) and an inhibitory potency against both en-
zymes (77 EeAChE IC50 = 7.91 M and EqBuChE IC50 = 
4.97 M). The results of docking studies showed that these 
compounds could act as dual-binding site inhibitors, interact-
ing with both the CAS and PAS of AChE. 
 
Fig. (40). Dual-acting diether derivatives of homopiperidine with 
histamine H3 receptor antagonistic and anticholinesterase activity. 
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Recently, Darras et al. [226] presented two novel series 
of tri- and tetracyclic nitrogen-bridgehead compounds act-
ing as dual AChE inhibitors and hH3 receptor antagonists. 
The target compounds were designed by connecting a tri- 
and tetracyclic fragment endowed with an inhibitory activ-
ity against cholinesterases with an amine moiety [227]. The 
amine moiety was based on the piperidinylpropoxyphenyl 
pharmacophore, which is characteristic for H3 receptor an-
tagonists (Fig. 41). New tetracyclic hybrids were moderate, 
non-selective AChE/BuChE inhibitors with IC50 values in 
the submicromolar to micromolar range. The compounds 
displayed affinity for hH3 receptors in a wide range. Com-
pound 79 (Fig. 41) showed high binding affinity at hH3R 
(Ki = 17.5 nM) but displayed a moderate inhibitory activity 
towards EeAChE (IC50 = 6.77 M) and EqBuChE (IC50 = 
1.07 M). The tricyclic hybrids represent moderate or po-
tent AChE inhibitors, with activities ranging from 8.91 M 
to 0.067 M for compound 80 (Fig. 41). Their activity to-
wards BuChE was in the micromolar range. Regarding, the 
hH3 receptor affinities, they were ranging from the micro-
moles to nanomoles for the most active compound 80 (Ki = 
76.2 nM). Moreover, all of the tested compounds showed a 
very good selectivity profile with regard to the hH3 receptor 
over all the other hH receptor subtypes (H1, H2 and H4). 
The most promising compound is the tricyclic hybrid 80, 
which is a reversible and competitive AChE inhibitor and 
an antagonist hH3R, with a balanced potency against both 
targets. 
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Fig. (41). Tri- and tetracyclic derivatives acting as dual AChE in-
hibitors and hH3 receptor antagonists. 
 
5-Lipoxygenase Inhibitors 
It has been proven that 5-lipoxygenase (5-LO) is con-
nected with A aggregation [228, 229] and its inhibition can 
reduce the formation of amyloid plaques in the brain [230]. 
Morover, 5-LO is involved in an inflammatory processes. 
Chen et al. [231] reported a series of an isoliquiritigenin 
(4,2’,4’-trihydroxychalcone, ISL) derivatives as new 5-LO 
and A aggregation inhibitors. Although the activity of the 
obtained compounds was not very diverse, certain structure-
activity relationships may be noted. The most potent inhibi-
tors contained a six-membered cyclic amine (N-
methylpiperazine, piperidine and morpholine) substituent at 
one of the phenyl rings. Compound 81 (Fig. 42) was found 
to be one of the most potent inhibitors with balanced activity 
against both 5-LO and A self-induced aggregation tested in 
the thioflavin T assay (IC50 = 6.1 M, IC50 = 3.2 M, respec-
tively). Its ability to inhibit -sheet aggregation and fibril 
formation was also confirmed in a circular dichroism 
spectroscopy assay and an electron microscopy assay. 
O
OH O
O
N
O
self-ind. A1-42 aggr. IC50 = 3.2 M
Lipoxygenase IC50 = 6.1 M
81
 
Fig. (42). An isoliquiritigenin derivative with activity against 5-LO 
and A aggregation. 
 
SUMMARY
The limited efficacy of the current AD therapy has led to 
the development of many different approaches in searching 
for new drug candidates. Among them, MTDLs strategy en-
ables researchers to obtain compounds endowed with advan-
tageous properties resulting from possible interactions with 
more than one target involved in the pathogenesis of AD. 
This review collects and presents novel compounds de-
scribed during the last three years, which were classified by 
the biological targets and chemical structure. The most 
common biological targets used for the development of 
MTDLs for AD are: acetylcholinesterase, butyrylcho-
linesterase, -secretase, -amyloid and monoamine oxidases. 
There is also a large number of compounds which display 
the antioxidant, metal chelating, neuroprotective and NO-
releasing activity. 
The majority of the research is focused on modifications 
of the existing drugs or already known structures with spe-
cific biological activity. Tacrine is among the most popular 
pharmacophores used for the design of MTDLs since it is 
very active cholinesterase inhibitor. There is also a number 
of hybrid compounds containing fragments of donepezil, 
galantamine or memantine. It is worth noting that there is a 
large group of hybrid compounds containing a structural 
fragments derived from natural sources. They are naturally 
occurring alkaloids, flavonoids or other natural products like 
isaindigotone, chelerythrine, chalcone, coumarin, huprine, 
curcumin, rhein, berberine and resveratrol derivatives. Ap-
plication of these less popular pharmacophores carries a 
greater risk of obtaining compounds with poor biological 
activity. On the other hand, this approach may indicate new 
directions for the development of new anti-AD drugs. 
Development of an effective drug for AD has proven to 
be very difficult. Even though there is a great number of very 
interesting compounds with diverse pharmacological profile 
in preclinical studies, the majority of them fail the clinical 
trials. The results of the analysis published by Cumming et
al. [232] showed that during the period between 2002 and 
2012 there were 413 AD clinical trials performed and only 
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one compound (memantine) was advanced to the FDA and 
approved for marketing. Currently, 108 clinical trials for AD 
therapies are being conducted, and only 14 agents reached 
phase 3. Ladostigil, the multifunctional agent which failed 
phase 3 clinical trials as AD drug, is currently investigated as 
potential agent for Mild Cognitive Impairment. The statistics 
indicate that there is no simple way of searching for AD 
therapy and the presented multi-target directed ligand ap-
proach gives hope for further development and for finding 
new and effective therapy for AD. 
ABBREVIATIONS 
5-LO = 5-lipoxygenase 
ABTS = 2,2’-azino-bis(3-ethylbenzthiazoline-6-
sulfonic acid); (2,2-diphenyl-1-
picrylhydrazyl) 
ACh = Acetylcholine 
AChE = Acetylcholinesterase 
AD = Alzheimer’s disease 
ADHD = Attention deficit hyperactivity disorder 
AFM = Atomic force microscopy 
AGE = Advanced glycation endproduct 
APP = Amyloid precursor protein 
A = -amyloid peptide 
BACE1 = -secretase, -site APP-cleaving enzyme 1 
BBB = Blood brain barier 
BTA = Benzothiazole 
BuChE = Butyrylcholinesterase 
CAS = Catalytic active site 
CB = Cannabinoid 
CNS = Central nervous system 
DPPH = Di(phenyl)-(2,4,6-
trinitrophenyl)iminoazanium 
EeAChE  = Acetylcholinesterase from Electrophorus 
electricus 
EqBuChE  = Butyrylcholinesterase from equine serum 
FDA = Food and Drug Administration 
FRET = Fluorescence resonance energy transfer 
GABA = -aminobutyric acid 
GO = Glucose oxidase 
GPSRs = G protein-coupled receptors 
GPx = Glutathione peroxidase 
H = Histamine 
H3R = Histamine H3 receptor 
hAChE  = Human acetylcholinesterase 
hBACE1 = Human -secretase 
hBuChE  = Human butyrylcholinesterase 
hH3R = Human histamine H3 receptor 
hMAO-A/B = Human monoamine oxidase A/B 
I = Inhibitor 
IPA = Indole-3-propionic acid 
MAO-A/B = Monoamine oxidase A/B 
MTDL = Multi-target-directed ligand 
NFTs = Neurofibrillary tangles 
NMDA = N-methyl-D-aspartate 
NO = Nitric oxide 
NSAIDs  = Nonsteroidal anti-inflammatory drugs 
ORAC-FL  = Oxygen radical absorbance capacity fluo-
rescein assay 
PAMPA = Parallel artificial membrane penetration assay 
PAS = Peripheral anionic site 
PPAR = Peroxisome proliferator-activated receptor 
rAChE = Acetylcholinesterase from rat brain 
rMAO-A/B = Monoamine oxidase A/B from rat brain 
ROS = Reactive oxygen species 
SAR = Structure-activity relationship 
Sin1 = Morpholinosydnonimine 
ThT = Thioflavin 
CONFLICT OF INTEREST 
The authors confirm that this article content has no con-
flict of interest. 
ACKNOWLEDGEMENTS 
This work was supported by the National Science Centre, 
Poland (grant No 2012/07/B/NZ7/04253) and Polish Minis-
try for Science and High Education (grant No IP2012 
063272). 
REFERENCES 
[1] Querfurth, H.W.; LaFerla, F.M. Alzheimer's disease. N. Engl. J. 
Med., 2010, 362, 329-344. 
[2] Huang, Y.; Mucke, L. Alzheimer Mechanisms and Therapeutic 
Strategies. Cell, 2012, 148, 1204-1222. 
[3] Reitz, C.; Brayne, C.; Mayeux, R. Epidemiology of Alzheimer 
disease. Nat. Rev. Neurol., 2011, 7, 137-152. 
[4] Reitz, C.; Mayeux, R. Alzheimer disease: Epidemiology, diagnostic 
criteria, risk factors and biomarkers. Biochem. Pharmacol., 2014,
88, 640-651. 
[5] Bartus, R.; Dean, R.; Beer, B.; Lippa, A. The cholinergic hypothe-
sis of geriatric memory dysfunction. Science, 1982, 217, 408-414. 
[6] Terry, A.V. Jr.; Buccafusco, J.J. The cholinergic hypothesis of age 
and Alzheimer's disease-related cognitive deficits: recent chal-
lenges and their implications for novel drug development. J. Phar-
macol. Exp. Ther., 2003, 306, 821-827. 
[7] Marksteiner, J.; Schmidt, R. Treatment strategies in Alzheimer's 
disease with a focus on early pharmacological interventions. Drugs 
Aging, 2004, 21, 415-426. 
[8] Meunier, J.; Ieni, J.; Maurice, T. The anti-amnesic and neuropro-
tective effects of donepezil against amyloid 25-35 peptide-induced 
toxicity in mice involve an interaction with the sigma1 receptor. Br. 
J. Pharmacol., 2006, 149, 998-1012. 
[9] Wilkinson, D. G.; Francis, P. T.; Schwam, E.; Payne-Parrish, J. 
Cholinesterase inhibitors used in the treatment of Alzheimer's dis-
Recent Development of Multifunctional Agents Current Medicinal Chemistry, 2015, Vol. 22, No. 3    399
ease: the relationship between pharmacological effects and clinical 
efficacy. Drugs Aging, 2004, 21, 453-478. 
[10] Rodda, J.; Carter, J. Cholinesterase inhibitors and memantine for 
symptomatic treatment of dementia. BMJ, 2012, 344, e2986. 
[11] van Marum, R. J. Current and future therapy in Alzheimer's dis-
ease. Fundam. Clin. Pharmacol., 2008, 22, 265-274. 
[12] Martinez, A. Emerging Drugs and Targets for Alzheimer’s Dis-
ease: Volume 1: Beta-Amyloid, Tau Protein and Glucose Metabo-
lism; RSC: Cambridge, UK, 2010.
[13] Martinez, A. Emerging Drugs and Targets for Alzheimer’s Dis-
ease: Volume 2: Neuronal Plasticity. RSC: Cambridge, UK, 2010.
[14] Grill, J. D.; Cummings, J. L. Current therapeutic targets for the 
treatment of Alzheimer's disease. Expert Rev. Neurother., 2010, 10, 
711-728. 
[15] Hardy, J.; Allsop, D. Amyloid deposition as the central event in the 
aetiology of Alzheimer's disease. Trends Pharmacol. Sci., 1991, 12, 
383-388. 
[16] Frisardi, V.; Solfrizzi, V.; Imbimbo, P.B.; Capurso, C.; D'Introno, 
A.; Colacicco, A.M.; Vendemiale, G.; Seripa, D.; Pilotto, A.; 
Capurso, A.; Panza, F. Towards disease-modifying treatment of 
Alzheimer's disease: drugs targeting beta-amyloid. Curr. Alzheimer 
Res., 2010, 7, 40-55. 
[17] Rampa, A.; Gobbi, S.; Belluti, F.; Bisi, A. Emerging targets in 
neurodegeneration: new opportunities for Alzheimer's disease 
treatment? Curr. Top. Med. Chem., 2013, 13, 1879-1904. 
[18] Caraci, F.; Bosco, P.; Leggio, G.M.; Malaguarnera, M.; Drago, F.; 
Bucolo, C.; Salomone, S. Clinical pharmacology of novel anti-
Alzheimer disease modifying medications. Curr. Top. Med. Chem., 
2013, 13, 1853-1863. 
[19] Bennett, D.A.; Yu, L.; De Jager, P.L. Building a pipeline to dis-
cover and validate novel therapeutic targets and lead compounds 
for Alzheimer's disease. Biochem. Pharmacol., 2014, 88, 617-630. 
[20] Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging 
drug discovery paradigm. J. Med. Chem., 2005, 48, 6523-6543. 
[21] Morphy, R.; Rankovic, Z. Designing multiple ligands - medicinal 
chemistry strategies and challenges. Curr. Pharm. Des., 2009, 15, 
587-600. 
[22] Espinoza-Fonseca, L.M. The benefits of the multi-target approach 
in drug design and discovery. Bioorg. Med. Chem., 2006, 14, 896-
897. 
[23] Muller-Schiffmann, A.; Sticht, H.; Korth, C. Hybrid compounds: 
from simple combinations to nanomachines. BioDrugs, 2012, 26, 
21-31. 
[24] Rapposelli, S.; Balsamo, A. In: Multifunctional drugs: new chime-
ras in medicinal chemistry; Rapposelli, S., Ed.; Transworld Re-
search Network: Kerala, 2010, pp. 1-17. 
[25] Nielsch, U.; Schafer, S.; Wild, H.; Busch, A. One target-multiple 
indications: a call for an integrated common mechanisms strategy. 
Drug Discov. Today, 2007, 12, 1025-1031. 
[26] Speck-Planche, A.; Luan, F.; Cordeiro, M.N. Role of ligand-based 
drug design methodologies toward the discovery of new anti-
Alzheimer agents: futures perspectives in Fragment-Based Ligand 
Design. Curr. Med. Chem., 2012, 19, 1635-1645. 
[27] Costantino, L.; Barlocco, D. Designed multiple ligands: basic re-
search vs clinical outcomes. Curr. Med. Chem., 2012, 19, 3353-
3387. 
[28] Anand, S.; VandeVrede, L.; Luo, J.; Thatcher, G.R. J. In: Multi-
functional drugs: new chimeras in medicinal chemistry; Rapposelli,
S., Ed.; Transworld Research Network: Kerala, 2010, pp. 65-97. 
[29] Cavalli, A.; Bolognesi, M.L. Multitarget drugs for the treatment of 
Alzheimer’s disease. In Polypharmacology in drug discovery; Pe-
ters, J. U., Ed.; Wiley: 2012, 441-448. 
[30] Iqbal, K.; Grundke-Iqbal, I. Alzheimer's disease, a multifactorial 
disorder seeking multitherapies. Alzheimers Dement., 2010, 6, 420-
424. 
[31] Bolognesi, M.L.; Matera, R.; Minarini, A.; Rosini, M.; Melchiorre, 
C. Alzheimer's disease: new approaches to drug discovery. Curr. 
Opin. Chem. Biol., 2009, 13, 303-308. 
[32] Calza, L.; Baldassarro, V.A.; Giuliani, A.; Lorenzini, L.; Fernan-
dez, M.; Mangano, C.; Sivilia, S.; Alessandri, M.; Gusciglio, M.; 
Torricella, R.; Giardino, L. From the multifactorial nature of Alz-
heimer`s disease to multitarget therapy: the contribution of the 
translational approach. Curr. Top. Med. Chem., 2013, 13, 1843-
1852. 
[33] Decker, M. Recent advances in the development of hybrid mole-
cules/designed multiple compounds with antiamnesic properties. 
Mini Rev. Med. Chem., 2007, 7, 221-229. 
[34] Musial, A.; Bajda, M.; Malawska, B. Recent developments in cho-
linesterases inhibitors for Alzheimer's disease treatment. Curr. 
Med. Chem., 2007, 14, 2654-2679. 
[35] Tumiatti, V.; Minarini, A.; Bolognesi, M.L.; Milelli, A.; Rosini, 
M.; Melchiorre, C. Tacrine derivatives and Alzheimer's disease. 
Curr. Med. Chem., 2010, 17, 1825-1838. 
[36] Cavalli, A.; Bolognesi, M.L.; Minarini, A.; Rosini, M.; Tumiatti, 
V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to 
combat neurodegenerative diseases. J. Med. Chem., 2008, 51, 347-
372. 
[37] Minarini, A.; Milelli, A.; Simoni, E.; Rosini, M.; Bolognesi, M.L.; 
Marchetti, C.; Tumiatti, V. Multifunctional tacrine derivatives in 
Alzheimer's disease. Curr. Top. Med. Chem., 2013, 13, 1771-1786. 
[38] Viayna, E.; Sabate, R.; Munoz-Torrero, D. Dual inhibitors of beta-
amyloid aggregation and acetylcholinesterase as multi-target anti-
Alzheimer drug candidates. Curr. Top. Med. Chem., 2013, 13, 
1820-1842. 
[39] Leon, R.; Garcia, A.G.; Marco-Contelles, J. Recent advances in the 
multitarget-directed ligands approach for the treatment of Alz-
heimer's disease. Med. Res. Rev., 2013, 33, 139-189. 
[40] Fernandez-Bachiller, M.I.; Perez, C.; Campillo, N.E.; Paez, J.A.; 
Gonzalez-Munoz, G.C.; Usan, P.; Garcia-Palomero, E.; Lopez, 
M.G.; Villarroya, M.; Garcia, A.G.; Martinez, A.; Rodriguez-
Franco, M.I. Tacrine-melatonin hybrids as multifunctional agents 
for Alzheimer's disease, with cholinergic, antioxidant, and neuro-
protective properties. ChemMedChem, 2009, 4, 828-841. 
[41] Samadi, A.; Valderas, C.; de los Ríos, C.; Bastida, A.; Chioua, M.; 
González-Lafuente, L.; Colmena, I.; Gandía, L.; Romero, A.; del 
Barrio, L.; Martín-de-Saavedra, M.D.; López, M.G.; Villarroya, 
M.; Marco-Contelles, J. Cholinergic and neuroprotective drugs for 
the treatment of Alzheimer and neuronal vascular diseases. II. Syn-
thesis, biological assessment, and molecular modelling of new 
tacrine analogues from highly substituted 2-aminopyridine-3-
carbonitriles. Bioorg. Med. Chem., 2011, 19, 122-133. 
[42] León, R.; Ríos, C. d. l.; Marco-Contelles, J.; Huertas, O.; Barril, X.; 
Javier Luque, F.; López, M. G.; García, A. G.; Villarroya, M. New 
tacrine-dihydropyridine hybrids that inhibit acetylcholinesterase, 
calcium entry, and exhibit neuroprotection properties. Bioorg. Med. 
Chem., 2008, 16, 7759-7769. 
[43] Tomassoli, I.; Ismaili, L.; Pudlo, M.; de los Ríos, C.; Soriano, E.; 
Colmena, I.; Gandía, L.; Rivas, L.; Samadi, A.; Marco-Contelles, J. 
Synthesis, biological assessment and molecular modeling of new 
dihydroquinoline-3-carboxamides and dihydroquinoline-3-
carbohydrazide derivatives as cholinesterase inhibitors, and Ca 
channel antagonists. Eur. J. Med. Chem., 2011, 46, 1-10. 
[44] Lange, J.H.; Coolen, H.K.; van der Neut, Martina A.W.; Borst, 
A.J.; Stork, B.; Verveer, P.C.; Kruse, C.G. Design, synthesis, bio-
logical properties, and molecular modeling investigations of novel 
tacrine derivatives with a combination of acetylcholinesterase inhi-
bition and cannabinoid CB1 receptor antagonism. J. Med. Chem., 
2010, 53, 1338-1346. 
[45] Piazzi, L.; Cavalli, A.; Colizzi, F.; Belluti, F.; Bartolini, M.; Manc-
ini, F.; Recanatini, M.; Andrisano, V.; Rampa, A. Multi-target-
directed coumarin derivatives: hAChE and BACE1 inhibitors as 
potential anti-Alzheimer compounds. Bioorg. Med. Chem. Lett., 
2008, 18, 423-426. 
[46] Zhu, Y.; Xiao, K.; Ma, L.; Xiong, B.; Fu, Y.; Yu, H.; Wang, W.; 
Wang, X.; Hu, D.; Peng, H.; Li, J.; Gong, Q.; Chai, Q.; Tang, X.; 
Zhang, H.; Li, J.; Shen, J. Design, synthesis and biological evalua-
tion of novel dual inhibitors of acetylcholinesterase and <br />-
secretase. Bioorg. Med. Chem., 2009, 17, 1600-1613. 
[47] Bertoni, S.; Ballabeni, V.; Flammini, L.; Saccani, F.; Domenichini, 
G.; Morini, G.; Comini, M.; Rivara, M.; Barocelli, E. In vitro and 
in vivo pharmacological analysis of imidazole-free histamine H3 re-
ceptor antagonists: promising results for a brain-penetrating H3
blocker with weak anticholinesterase activity. Naunyn Schmiede-
bergs Arch. Pharmacol., 2008, 378, 335-343. 
[48] Incerti, M.; Flammini, L.; Saccani, F.; Morini, G.; Comini, M.; 
Coruzzi, M.; Barocelli, E.; Ballabeni, V.; Bertoni, S. DualActing 
Drugs: an in vitro Study of Nonimidazole Histamine H3 Receptor 
Antagonists Combining Anticholinesterase Activity. ChemMed-
Chem, 2010, 5, 1143-1149. 
[49] Rook, Y.; Schmidtke, K.; Gaube, F.; Schepmann, D.; Wü nsch, 
B.; Heilmann, J.; Lehmann, J.; Winckler, T. Bivalent -carbolines 
as potential multitarget anti-Alzheimer agents. J. Med. Chem., 
2010, 53, 3611-3617. 
[50] Rosini, M.; Simoni, E.; Bartolini, M.; Cavalli, A.; Ceccarini, L.; 
Pascu, N.; McClymont, D.W.; Tarozzi, A.; Bolognesi, M.L.; 
Minarini, A. Inhibition of acetylcholinesterase, -amyloid aggrega-
tion, and NMDA receptors in Alzheimer’s disease: a promising di-
rection for the multi-target-directed ligands gold rush. J. Med. 
Chem., 2008, 51, 4381-4384. 
400    Current Medicinal Chemistry, 2015, Vol. 22, No. 3 Guzior et al. 
[51] Cappelli, A.; Gallelli, A.; Manini, M.; Anzini, M.; Mennuni, L.; 
Makovec, F.; Menziani, M.C.; Alcaro, S.; Ortuso, F.; Vomero, S. 
Further studies on the interaction of the 5-hydroxytryptamine3 (5-
HT3) receptor with arylpiperazine ligands. Development of a new 
5-HT3 receptor ligand showing potent acetylcholinesterase inhibi-
tory properties. J. Med. Chem., 2005, 48, 3564-3575. 
[52] Toda, N.; Kaneko, T.; Kogen, H. Development of an efficient 
therapeutic agent for Alzheimer's disease: design and synthesis of 
dual inhibitors of acetylcholinesterase and serotonin transporter. 
Chem. Pharm. Bull., 2010, 58, 273-287. 
[53] Fernández-Bachiller, M.I.; Pérez, C.; González-Munoz, G.C.; 
Conde, S.; López, M.G.; Villarroya, M.; García, A.G.; Rodríguez-
Franco, M.I. Novel tacrine 8-hydroxyquinoline hybrids as multi-
functional agents for the treatment of Alzheimer’s disease, with 
neuroprotective, cholinergic, antioxidant, and copper-complexing 
properties. J. Med. Chem., 2010, 53, 4927-4937. 
[54] Huang, W.; Lv, D.; Yu, H.; Sheng, R.; Kim, S. C.; Wu, P.; Luo, K.; 
Li, J.; Hu, Y. Dual-target-directed 1, 3-diphenylurea derivatives: 
BACE 1 inhibitor and metal chelator against Alzheimer’s disease. 
Bioorg. Med. Chem., 2010, 18, 5610-5615. 
[55] AvramovichTirosh, Y.; Amit, T.; BarAm, O.; Zheng, H.; Fridkin, 
M.; Youdim, M.B. Therapeutic targets and potential of the novel 
brainpermeable multifunctional iron chelator-monoamine oxidase 
inhibitor drug, M30, for the treatment of Alzheimer's disease1. J. 
Neurochem., 2007, 100, 490-502. 
[56] Zheng, H.; Youdim, M.B.; Fridkin, M. Site-activated multifunc-
tional chelator with acetylcholinesterase and neuroprotective  neu-
rorestorative moieties for Alzheimer’s therapy. J. Med. Chem., 
2009, 52, 4095-4098. 
[57] Hieke, M.; Ness, J.; Steri, R.; Dittrich, M.; Greiner, C.; Werz, O.; 
Baumann, K.; Schubert-Zsilavecz, M.; Weggen, S.; Zettl, H. De-
sign, synthesis, and biological evaluation of a novel class of -
secretase modulators with PPAR activity. J. Med. Chem., 2010,
53, 4691-4700. 
[58] Li, W.; Mak, M.; Jiang, H.; Wang, Q.; Pang, Y.; Chen, K.; Han, Y. 
Novel anti-Alzheimer's dimer Bis(7)-cognitin: cellular and molecu-
lar mechanisms of neuroprotection through multiple targets. Neu-
rotherapeutics, 2009, 6, 187-201. 
[59] Weinreb, O.; Amit, T.; Bar-Am, O.; Youdim, M.B. Ladostigil: a 
novel multimodal neuroprotective drug with cholinesterase and 
brain-selective monoamine oxidase inhibitory activities for Alz-
heimer's disease treatment. Curr. Drug Targets, 2012, 13, 483-494. 
[60] Capurro, V.; Busquet, P.; Lopes, J.P.; Bertorelli, R.; Tarozzo, G.; 
Bolognesi, M.L.; Piomelli, D.; Reggiani, A.; Cavalli, A. Pharma-
cological characterization of memoquin, a multi-target compound 
for the treatment of Alzheimer's disease. PLoS One, 2013, 8, 
e56870. 
[61] Carreiras, M.C.; Mendes, E.; Perry, M.J.; Francisco, A.P.; Marco-
Contelles, J. The multifactorial nature of Alzheimer's disease for 
developing potential therapeutics. Curr. Top. Med. Chem., 2013,
13, 1745-1770. 
[62] Agis-Torres, A.; Solhuber, M.; Fernandez, M.; Sanchez-Montero, 
J.M. Multi-target-directed ligands and other therapeutic strategies 
in the search of a real solution for Alzheimer's disease. Curr. Neu-
ropharmacol., 2014, 12, 2-36. 
[63] Bajda, M.; Guzior, N.; Ignasik, M.; Malawska, B. Multi-target-
directed ligands in Alzheimer's disease treatment. Curr. Med. 
Chem., 2011, 18, 4949-4975. 
[64] Lane, R.M.; Potkin, S.G.; Enz, A. Targeting acetylcholinesterase 
and butyrylcholinesterase in dementia. Int. J. Neuropsychopharma-
col., 2006, 9, 101-124. 
[65] Darvesh, S.; Hopkins, D.A.; Geula, C. Neurobiology of butyrylcho-
linesterase. Nat. Rev. Neurosci., 2003, 4, 131-138. 
[66] Mesulam, M.M.; Guillozet, A.; Shaw, P.; Levey, A.; Duysen, E.G.; 
Lockridge, O. Acetylcholinesterase knockouts establish central 
cholinergic pathways and can use butyrylcholinesterase to hydro-
lyze acetylcholine. Neuroscience, 2002, 110, 627-639. 
[67] Reid, G.A.; Chilukuri, N.; Darvesh, S. Butyrylcholinesterase and 
the cholinergic system. Neuroscience, 2013, 234, 53-68. 
[68] Greig, N.H.; Utsuki, T.; Ingram, D.K.; Wang, Y.; Pepeu, G.; Scali, 
C.; Yu, Q.S.; Mamczarz, J.; Holloway, H.W.; Giordano, T.; Chen, 
D.; Furukawa, K.; Sambamurti, K.; Brossi, A.; Lahiri, D.K. Selec-
tive butyrylcholinesterase inhibition elevates brain acetylcholine, 
augments learning and lowers Alzheimer -amyloid peptide in ro-
dent. Proc. Natl. Acad. Sci. U. S. A., 2005, 102, 17213-17218. 
[69] Diamant, S.; Podoly, E.; Friedler, A.; Ligumsky, H.; Livnah, O.; 
Soreq, H. Butyrylcholinesterase attenuates amyloid fibril formation 
in vitro. Proc. Natl. Acad. Sci. U. S. A., 2006, 103, 8628-8633. 
[70] Podoly, E.; Shalev, D.E.; Shenhar-Tsarfaty, S.; Bennett, E.R.; Ben 
Assayag, E.; Wilgus, H.; Livnah, O.; Soreq, H. The butyrylcho-
linesterase K variant confers structurally derived risks for Alz-
heimer pathology. J. Biol. Chem., 2009, 284, 17170-17179. 
[71] Bartolini, M.; Bertucci, C.; Cavrini, V.; Andrisano, V. beta-
Amyloid aggregation induced by human acetylcholinesterase: inhi-
bition studies. Biochem. Pharmacol., 2003, 65, 407-416. 
[72] Dinamarca, M.C.; Sagal, J.P.; Quintanilla, R.A.; Godoy, J.A.; Ar-
razola, M.S.; Inestrosa, N.C. Amyloid-beta-Acetylcholinesterase 
complexes potentiate neurodegenerative changes induced by the 
Abeta peptide. Implications for the pathogenesis of Alzheimer's 
disease. Mol. Neurodegener., 2010, 5, 4-1326-5-4. 
[73] Giacobini, E. Cholinesterase inhibitors: new roles and therapeutic 
alternatives. Pharmacol. Res., 2004, 50, 433-440. 
[74] Pepeu, G.; Giovannini, M.G. Cholinesterase inhibitors and beyond. 
Curr. Alzheimer Res., 2009, 6, 86-96. 
[75] Darreh-Shori, T.; Soininen, H. Effects of cholinesterase inhibitors 
on the activities and protein levels of cholinesterases in the cere-
brospinal fluid of patients with Alzheimer's disease: a review of re-
cent clinical studies. Curr. Alzheimer Res., 2010, 7, 67-73. 
[76] Romero, A.; Cacabelos, R.; Oset-Gasque, M.J.; Samadi, A.; 
Marco-Contelles, J. Novel tacrine-related drugs as potential candi-
dates for the treatment of Alzheimer's disease. Bioorg. Med. Chem. 
Lett., 2013, 23, 1916-1922. 
[77] Tang, H.; Zhao, L.Z.; Zhao, H.T.; Huang, S.L.; Zhong, S.M.; Qin, 
J.K.; Chen, Z.F.; Huang, Z.S.; Liang, H. Hybrids of oxoisoapor-
phine-tacrine congeners: novel acetylcholinesterase and acetylcho-
linesterase-induced -amyloid aggregation inhibitors. Eur. J. Med. 
Chem., 2011, 46, 4970-4979. 
[78] Tang, H.; Wei, Y.B.; Zhang, C.; Ning, F.X.; Qiao, W.; Huang, 
S.L.; Ma, L.; Huang, Z.S.; Gu, L.Q. Synthesis, biological evalua-
tion and molecular modeling of oxoisoaporphine and oxoaporphine 
derivatives as new dual inhibitors of acetylcho-
linesterase/butyrylcholinesterase. Eur. J. Med. Chem., 2009, 44, 
2523-2532. 
[79] Tang, H.; Ning, F.X.; Wei, Y.B.; Huang, S.L.; Huang, Z.S.; Chan, 
A.S.; Gu, L.Q. Derivatives of oxoisoaporphine alkaloids: a novel 
class of selective acetylcholinesterase inhibitors. Bioorg. Med. 
Chem. Lett., 2007, 17, 3765-3768. 
[80] Ellman, G.L.; Courtney, K.D.; Andres jr.,V.; Featherstone, R.M. A 
new and rapid colorimetric determination of acetylcholinesterase 
activity. Biochem. Pharmacol., 1961, 7, 88-95. 
[81] LeVine, H. 3rd Thioflavine T interaction with synthetic Alz-
heimer's disease -amyloid peptides: detection of amyloid aggrega-
tion in solution. Protein Sci., 1993, 2, 404-410. 
[82] Keri, R.S.; Quintanova, C.; Marques, S.M.; Esteves, A.R.; Cardoso, 
S.M.; Santos, M.A. Design, synthesis and neuroprotective evalua-
tion of novel tacrine-benzothiazole hybrids as multi-targeted com-
pounds against Alzheimer's disease. Bioorg. Med. Chem., 2013, 21, 
4559-4569. 
[83] Leuma Yona, R.; Mazeres, S.; Faller, P.; Gras, E. Thioflavin de-
rivatives as markers for amyloid-beta fibrils: insights into structural 
features important for high-affinity binding. ChemMedChem, 2008,
3, 63-66. 
[84] Choi, M.M.; Kim, E.A.; Hahn, H.G.; Nam, K.D.; Yang, S.J.; Choi, 
S.Y.; Kim, T.U.; Cho, S.W.; Huh, J.W. Protective effect of ben-
zothiazole derivative KHG21834 on amyloid -induced neurotoxic-
ity in PC12 cells and cortical and mesencephalic neurons. Toxicol-
ogy, 2007, 239, 156-166. 
[85] Soto-Ortega, D.D.; Murphy, B.P.; Gonzalez-Velasquez, F.J.; Wil-
son, K.A.; Xie, F.; Wang, Q.; Moss, M.A. Inhibition of amyloid-
aggregation by coumarin analogs can be manipulated by function-
alization of the aromatic center. Bioorg. Med. Chem., 2011, 19, 
2596-2602. 
[86] Ozturan Ozer, E.; Tan, O.U.; Ozadali, K.; Kucukkilinc, T.; Balkan, 
A.; Ucar, G. Synthesis, molecular modeling and evaluation of 
novel N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone de-
rivatives as dual inhibitors for cholinesterases and A aggregation. 
Bioorg. Med. Chem. Lett., 2013, 23, 440-443. 
[87] Ignasik, M.; Bajda, M.; Guzior, N.; Prinz, M.; Holzgrabe, U.; Ma-
lawska, B. Design, synthesis and evaluation of novel 2-
(aminoalkyl)-isoindoline-1,3-dione derivatives as dual-binding site 
acetylcholinesterase inhibitors. Arch. Pharm. (Weinheim), 2012,
345, 509-516. 
[88] Bajda, M.; Wieckowska, A.; Hebda, M.; Guzior, N.; Sotriffer, 
C.A.; Malawska, B. Structure-based search for new inhibitors of 
cholinesterases. Int. J. Mol. Sci., 2013, 14, 5608-5632. 
[89] Alptuzun, V.; Prinz, M.; Horr, V.; Scheiber, J.; Radacki, K.; Fallar-
ero, A.; Vuorela, P.; Engels, B.; Braunschweig, H.; Erciyas, E.; 
Holzgrabe, U. Interaction of (benzylidene-hydrazono)-1,4-
dihydropyridines with -amyloid, acetylcholine, and butyrylcholine 
esterases. Bioorg. Med. Chem., 2010, 18, 2049-2059. 
Recent Development of Multifunctional Agents Current Medicinal Chemistry, 2015, Vol. 22, No. 3    401
[90] Catto, M.; Berezin, A.A.; Lo Re, D.; Loizou, G.; Demetriades, M.; 
De Stradis, A.; Campagna, F.; Koutentis, P.A.; Carotti, A. Design, 
synthesis and biological evaluation of benzo[e][1,2,4]triazin-7(1H)-
one and [1,2,4]-triazino[5,6,1-jk]carbazol-6-one derivatives as dual 
inhibitors of beta-amyloid aggregation and acetyl/butyryl cholines-
terase. Eur. J. Med. Chem., 2012, 58, 84-97. 
[91] Convertino, M.; Pellarin, R.; Catto, M.; Carotti, A.; Caflisch, A. 9, 
10-Anthraquinone hinders -aggregation: how does a small mole-
cule interfere with A-peptide amyloid fibrillation? Protein Sci., 
2009, 18, 792-800. 
[92] Karlsson, D.; Fallarero, A.; Brunhofer, G.; Guzik, P.; Prinz, M.; 
Holzgrabe, U.; Erker, T.; Vuorela, P. Identification and characteri-
zation of diarylimidazoles as hybrid inhibitors of butyrylcho-
linesterase and amyloid beta fibril formation. Eur. J. Pharm. Sci., 
2012, 45, 169-183. 
[93] Wu, X.; Qin, G.; Cheung, K.K.; Cheng, K.F. New alkaloids from 
Isatis indigotica. Tetrahedron, 1997, 53, 13323-13328. 
[94] Pan, L.; Tan, J.H.; Hou, J.Q.; Huang, S.L.; Gu, L.Q.; Huang, Z.S. 
Design, synthesis and evaluation of isaindigotone derivatives as 
acetylcholinesterase and butyrylcholinesterase inhibitors. Bioorg. 
Med. Chem. Lett., 2008, 18, 3790-3793. 
[95] Yan, J.W.; Li, Y.P.; Ye, W.J.; Chen, S.B.; Hou, J.Q.; Tan, J.H.; Ou, 
T.M.; Li, D.; Gu, L.Q.; Huang, Z.S. Design, synthesis and evalua-
tion of isaindigotone derivatives as dual inhibitors for acetylcho-
linesterase and amyloid beta aggregation. Bioorg. Med. Chem., 
2012, 20, 2527-2534. 
[96] Huang, L.; Su, T.; Li, X. Natural products as sources of new lead 
compounds for the treatment of Alzheimer's disease. Curr. Top. 
Med. Chem., 2013, 13, 1864-1878. 
[97] Brunhofer, G.; Fallarero, A.; Karlsson, D.; Batista-Gonzalez, A.; 
Shinde, P.; Gopi Mohan, C.; Vuorela, P. Exploration of natural 
compounds as sources of new bifunctional scaffolds targeting cho-
linesterases and beta amyloid aggregation: the case of chel-
erythrine. Bioorg. Med. Chem., 2012, 20, 6669-6679. 
[98] Anand, P.; Singh, B.; Singh, N. A review on coumarins as acetyl-
cholinesterase inhibitors for Alzheimer's disease. Bioorg. Med. 
Chem., 2012, 20, 1175-1180. 
[99] Hasan, A.; Khan, K.M.; Sher, M.; Maharvi, G.M.; Nawaz, S.A.; 
Choudhary, M.I.; Atta-ur-Rahman; Supuran, C.T. Synthesis and 
inhibitory potential towards acetylcholinesterase, butyrylcho-
linesterase and lipoxygenase of some variably substituted chal-
cones. J. Enzyme Inhib. Med. Chem., 2005, 20, 41-47. 
[100] Bag, S.; Ghosh, S.; Tulsan, R.; Sood, A.; Zhou, W.; Schifone, C.; 
Foster, M.; LeVine, H., 3rd; Torok, B.; Torok, M. Design, synthe-
sis and biological activity of multifunctional alpha,beta-unsaturated 
carbonyl scaffolds for Alzheimer's disease. Bioorg. Med. Chem. 
Lett., 2013, 23, 2614-2618. 
[101] LeVine, H. 3rd Biotin-avidin interaction-based screening assay for 
Alzheimer's -peptide oligomer inhibitors. Anal. Biochem., 2006,
356, 265-272. 
[102] Hong, L.; Koelsch, G.; Lin, X.; Wu, S.; Terzyan, S.; Ghosh, A.K.; 
Zhang, X.C.; Tang, J. Structure of the protease domain of me-
mapsin 2 (-secretase) complexed with inhibitor. Science, 2000,
290, 150-153. 
[103] Venugopal, C.; Demos, C.M.; Rao, K.S.; Pappolla, M.A.; Samba-
murti, K. Beta-secretase: structure, function, and evolution. CNS 
Neurol. Disord. Drug Targets, 2008, 7, 278-294. 
[104] Klaver, D.W.; Wilce, M.C.; Cui, H.; Hung, A.C.; Gasperini, R.; 
Foa, L.; Small, D.H. Is BACE1 a suitable therapeutic target for the 
treatment of Alzheimer's disease? Current strategies and future di-
rections. Biol. Chem., 2010, 391, 849-859. 
[105] Luo, X.; Yan, R. Inhibition of BACE1 for therapeutic use in Alz-
heimer's disease. Int. J. Clin. Exp. Pathol., 2010, 3, 618-628. 
[106] Bjorklund, C.; Oscarson, S.; Benkestock, K.; Borkakoti, N.; Jans-
son, K.; Lindberg, J.; Vrang, L.; Hallberg, A.; Rosenquist, A.; 
Samuelsson, B. Design and synthesis of potent and selective 
BACE-1 inhibitors. J. Med. Chem., 2010, 53, 1458-1464. 
[107] Ghosh, A.K.; Brindisi, M.; Tang, J. Developing -secretase inhibi-
tors for treatment of Alzheimer's disease. J. Neurochem., 2012, 120 
Suppl. 1, 71-83. 
[108] Fernandez-Bachiller, M.I.; Perez, C.; Monjas, L.; Rademann, J.; 
Rodriguez-Franco, M.I. New tacrine-4-oxo-4H-chromene hybrids 
as multifunctional agents for the treatment of Alzheimer's disease, 
with cholinergic, antioxidant, and -amyloid-reducing properties. J. 
Med. Chem., 2012, 55, 1303-1317. 
[109] Kennedy, M.E.; Wang, W.; Song, L.; Lee, J.; Zhang, L.; Wong, G.; 
Wang, L.; Parker, E. Measuring human -secretase (BACE1) activ-
ity using homogeneous time-resolved fluorescence. Anal. Bio-
chem., 2003, 319, 49-55. 
[110] Mancini, F.; De Simone, A.; Andrisano, V. Beta-secretase as a 
target for Alzheimer's disease drug discovery: an overview of in vi-
tro methods for characterization of inhibitors. Anal. Bioanal. 
Chem., 2011, 400, 1979-1996. 
[111] Davalos, A.; Gomez-Cordoves, C.; Bartolome, B. Extending appli-
cability of the oxygen radical absorbance capacity (ORAC-
fluorescein) assay. J. Agric. Food Chem., 2004, 52, 48-54. 
[112] Di, L.; Kerns, E.H.; Fan, K.; McConnell, O.J.; Carter, G.T. High 
throughput artificial membrane permeability assay for blood-brain 
barrier. Eur. J. Med. Chem., 2003, 38, 223-232. 
[113] Galdeano, C.; Viayna, E.; Sola, I.; Formosa, X.; Camps, P.; Badia, 
A.; Clos, M.V.; Relat, J.; Ratia, M.; Bartolini, M.; Mancini, F.; An-
drisano, V.; Salmona, M.; Minguillon, C.; Gonzalez-Munoz, G.C.; 
Rodriguez-Franco, M.I.; Bidon-Chanal, A.; Luque, F.J.; Munoz-
Torrero, D. Huprine-tacrine heterodimers as anti-amyloidogenic 
compounds of potential interest against Alzheimer's and prion dis-
eases. J. Med. Chem., 2012, 55, 661-669. 
[114] Viayna, E.; Sola, I.; Bartolini, M.; De Simone, A.; Tapia-Rojas, C.; 
Serrano, F.G.; Sabate, R.; Juarez-Jimenez, J.; Perez, B.; Luque, 
F.J.; Andrisano, V.; Clos, M.V.; Inestrosa, N.C.; Munoz-Torrero, 
D. Synthesis and multitarget biological profiling of a novel family 
of rhein derivatives as disease-modifying anti-Alzheimer agents. J. 
Med. Chem., 2014, 57, 2549-2567. 
[115] Mohamed, T.; Zhao, X.; Habib, L.K.; Yang, J.; Rao, P.P. Design, 
synthesis and structure-activity relationship (SAR) studies of 2,4-
disubstituted pyrimidine derivatives: dual activity as cholinesterase 
and A-aggregation inhibitors. Bioorg. Med. Chem., 2011, 19, 
2269-2281. 
[116] Mohamed, T.; Yeung, J.C.; Rao, P.P. Development of 2-
substituted-N-(naphth-1-ylmethyl) and N-benzhydrylpyrimidin-4-
amines as dual cholinesterase and A-aggregation inhibitors: Syn-
thesis and biological evaluation. Bioorg. Med. Chem. Lett., 2011,
21, 5881-5887. 
[117] Mohamed, T.; Yeung, J.C.; Vasefi, M.S.; Beazely, M.A.; Rao, P.P. 
Development and evaluation of multifunctional agents for potential 
treatment of Alzheimer's disease: application to a pyrimidine-2,4-
diamine template. Bioorg. Med. Chem. Lett., 2012, 22, 4707-4712. 
[118] Peng, D.Y.; Sun, Q.; Zhu, X.L.; Lin, H.Y.; Chen, Q.; Yu, N.X.; 
Yang, W.C.; Yang, G.F. Design, synthesis, and bioevaluation of 
benzamides: novel acetylcholinesterase inhibitors with multi-
functions on butylcholinesterase, Abeta aggregation, and -
secretase. Bioorg. Med. Chem., 2012, 20, 6739-6750. 
[119] Jiaranaikulwanitch, J.; Govitrapong, P.; Fokin, V.V.; Vajragupta, 
O. From BACE1 inhibitor to multifunctionality of tryptoline and 
tryptamine triazole derivatives for Alzheimer's disease. Molecules, 
2012, 17, 8312-8333. 
[120] Jiaranaikulwanitch, J.; Boonyarat, C.; Fokin, V.V.; Vajragupta, O. 
Triazolyl tryptoline derivatives as -secretase inhibitors. Bioorg. 
Med. Chem. Lett., 2010, 20, 6572-6576. 
[121] Sharma, O.P.; Bhat, T.K. DPPH antioxidant assay revisited. Food 
Chem., 2009, 113, 1202-1205. 
[122] Weinreb, O.; Mandel, S.; Bar-Am, O.; Amit, T. Iron-chelating 
backbone coupled with monoamine oxidase inhibitory moiety as 
novel pluripotential therapeutic agents for Alzheimer's disease: a 
tribute to Moussa Youdim. J. Neural Transm., 2011, 118, 479-492. 
[123] Song, M.S.; Matveychuk, D.; MacKenzie, E.M.; Duchcherer, M.; 
Mousseau, D.D.; Baker, G.B. An update on amine oxidase inhibi-
tors: multifaceted drugs. Prog. Neuropsychopharmacol. Biol. Psy-
chiatr., 2013, 44, 118-124. 
[124] Zheng, H.; Fridkin, M.; Youdim, M. From single target to multitar-
get/network therapeutics in Alzheimer's therapy. Pharmaceuticals 
(Basel), 2014, 7, 113-135. 
[125] Bolea, I.; Gella, A.; Unzeta, M. Propargylamine-derived multitar-
get-directed ligands: fighting Alzheimer's disease with monoamine 
oxidase inhibitors. J. Neural. Transm., 2013, 120, 893-902. 
[126] Bolea, I.; Juárez-Jiménez, J.; de, l.R.; Chioua, M.; Pouplana, R.; 
Luque, F.J.; Unzeta, M.; Marco-Contelles, J.; Samadi, A. Synthe-
sis, biological evaluation, and molecular modeling of donepezil and 
N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-
2-yn-1-amine hybrids as new multipotent cholinester-
ase/monoamine oxidase inhibitors for the treatment of Alzheimer’s 
disease. J. Med. Chem., 2011, 54, 8251-8270. 
[127] Perez, V.; Marco, J.L.; Fernandez-Alvarez, E.; Unzeta, M. Rele-
vance of benzyloxy group in 2-indolyl methylamines in the selec-
tive MAO-B inhibition. Br. J. Pharmacol., 1999, 127, 869-876. 
[128] Bolea, I.; Gella, A.; Monjas, L.; Perez, C.; Rodriguez-Franco, M.I.; 
Marco-Contelles, J.; Samadi, A.; Unzeta, M. Multipotent, perme-
able drug ASS234 inhibits Abeta aggregation, possesses antioxi-
dant properties and protects from A-induced apoptosis in vitro.
Curr. Alzheimer Res., 2013, 10, 797-808. 
402    Current Medicinal Chemistry, 2015, Vol. 22, No. 3 Guzior et al. 
[129] Bautista-Aguilera, O.M.; Esteban, G.; Bolea, I.; Nikolic, K.; Ag-
baba, D.; Moraleda, I.; Iriepa, I.; Samadi, A.; Soriano, E.; Unzeta, 
M.; Marco-Contelles, J. Design, synthesis, pharmacological evalua-
tion, QSAR analysis, molecular modeling and ADMET of novel 
donepezil-indolyl hybrids as multipotent cholinesterase/monoamine 
oxidase inhibitors for the potential treatment of Alzheimer's dis-
ease. Eur. J. Med. Chem., 2014, 75, 82-95. 
[130] Samadi, A.; de los Rios, C.; Bolea, I.; Chioua, M.; Iriepa, I.; 
Moraleda, I.; Bartolini, M.; Andrisano, V.; Galvez, E.; Valderas, 
C.; Unzeta, M.; Marco-Contelles, J. Multipotent MAO and cholin-
esterase inhibitors for the treatment of Alzheimer's disease: synthe-
sis, pharmacological analysis and molecular modeling of hetero-
cyclic substituted alkyl and cycloalkyl propargyl amine. Eur. J. 
Med. Chem., 2012, 52, 251-262. 
[131] Lu, C.; Zhou, Q.; Yan, J.; Du, Z.; Huang, L.; Li, X. A novel series 
of tacrine-selegiline hybrids with cholinesterase and monoamine 
oxidase inhibition activities for the treatment of Alzheimer's dis-
ease. Eur. J. Med. Chem., 2013, 62, 745-753. 
[132] Sun, Y.; Chen, J.; Chen, X.; Huang, L.; Li, X. Inhibition of cholin-
esterase and monoamine oxidase-B activity by Tacrine-
Homoisoflavonoid hybrids. Bioorg. Med. Chem. 2013, 21, 7406-
7417. 
[133] Desideri, N.; Bolasco, A.; Fioravanti, R.; Monaco, L. P.; Orallo, F.; 
Yanez, M.; Ortuso, F.; Alcaro, S. Homoisoflavonoids: natural scaf-
folds with potent and selective monoamine oxidase-B inhibition 
properties. J. Med. Chem., 2011, 54, 2155-2164. 
[134] Karuppasamy, M.; Mahapatra, M.; Yabanoglu, S.; Ucar, G.; Sinha, 
B.N.; Basu, A.; Mishra, N.; Sharon, A.; Kulandaivelu, U.; Jayapra-
kash, V. Development of selective and reversible pyrazoline based 
MAO-A inhibitors: Synthesis, biological evaluation and docking 
studies. Bioorg. Med. Chem., 2010, 18, 1875-1881. 
[135] Gokhan-Kelekci, N.; Yabanoglu, S.; Kupeli, E.; Salgin, U.; Ozgen, 
O.; Ucar, G.; Yesilada, E.; Kendi, E.; Yesilada, A.; Bilgin, A.A. A 
new therapeutic approach in Alzheimer disease: some novel pyra-
zole derivatives as dual MAO-B inhibitors and antiinflammatory 
analgesics. Bioorg. Med. Chem., 2007, 15, 5775-5786. 
[136] Mishra, N.; Sasmal, D. Development of selective and reversible 
pyrazoline based MAO-B inhibitors: virtual screening, synthesis 
and biological evaluation. Bioorg. Med. Chem. Lett., 2011, 21, 
1969-1973. 
[137] Mishra, N.; Sasmal, D. Additional acetyl cholinesterase inhibitory 
property of diaryl pyrazoline derivatives. Bioorg. Med. Chem. Lett., 
2013, 23, 702-705. 
[138] Feng, Y.; Wang, X. Antioxidant therapies for Alzheimer's disease. 
Oxid. Med. Cell Longev., 2012, 2012, 472932.
[139] Padurariu, M.; Ciobica, A.; Lefter, R.; Serban, I.L.; Stefanescu, C.; 
Chirita, R. The oxidative stress hypothesis in Alzheimer's disease. 
Psychiatr. Danub., 2013, 25, 401-409. 
[140] Shan, W.J.; Huang, L.; Zhou, Q.; Meng, F.C.; Li, X.S. Synthesis, 
biological evaluation of 9-N-substituted berberine derivatives as 
multi-functional agents of antioxidant, inhibitors of acetylcho-
linesterase, butyrylcholinesterase and amyloid- aggregation. Eur. 
J. Med. Chem., 2011, 46, 5885-5893. 
[141] Huang, L.; Luo, Z.; He, F.; Lu, J.; Li, X. Synthesis and biological 
evaluation of a new series of berberine derivatives as dual inhibi-
tors of acetylcholinesterase and butyrylcholinesterase. Bioorg. 
Med. Chem., 2010, 18, 4475-4484. 
[142] Huang, L.; Shi, A.; He, F.; Li, X. Synthesis, biological evaluation, 
and molecular modeling of berberine derivatives as potent acetyl-
cholinesterase inhibitors. Bioorg. Med. Chem., 2010, 18, 1244-
1251. 
[143] Su, T.; Xie, S.; Wei, H.; Yan, J.; Huang, L.; Li, X. Synthesis and 
biological evaluation of berberine-thiophenyl hybrids as multi-
functional agents: Inhibition of acetylcholinesterase, butyrylcho-
linesterase, and A aggregation and antioxidant activity. Bioorg. 
Med. Chem., 2013, 21, 5830-5840. 
[144] Maalej, E.; Chabchoub, F.; Samadi, A.; de los Rios, C.; Perona, A.; 
Morreale, A.; Marco-Contelles, J. Synthesis, biological assessment 
and molecular modeling of 14-aryl-10,11,12,14-tetrahydro-9H-
benzo[5,6]chromeno[2,3-b]quinolin-13-amines. Bioorg. Med. 
Chem. Lett., 2011, 21, 2384-2388. 
[145] Maalej, E.; Chabchoub, F.; Oset-Gasque, M.J.; Esquivias-Perez, 
M.; Gonzalez, M.P.; Monjas, L.; Perez, C.; de los Rios, C.; Rodri-
guez-Franco, M.I.; Iriepa, I.; Moraleda, I.; Chioua, M.; Romero, A.; 
Marco-Contelles, J.; Samadi, A. Synthesis, biological assessment, 
and molecular modeling of racemic 7-aryl-9,10,11,12-tetrahydro-
7H-benzo[7,8]chromeno[2,3-b]quinolin-8-amines as potential 
drugs for the treatment of Alzheimer's disease. Eur. J. Med. Chem., 
2012, 54, 750-763. 
[146] Songsiang, U.; Thongthoom, T.; Boonyarat, C.; Yenjai, C. 
Claurailas A-D, cytotoxic carbazole alkaloids from the roots of 
Clausena harmandiana. J. Nat. Prod., 2011, 74, 208-212. 
[147] Thiratmatrakul, S.; Yenjai, C.; Waiwut, P.; Vajragupta, O.; 
Reubroycharoen, P.; Tohda, M.; Boonyarat, C. Synthesis, biologi-
cal evaluation and molecular modeling study of novel tacrine-
carbazole hybrids as potential multifunctional agents for the treat-
ment of Alzheimer's disease. Eur. J. Med. Chem., 2014, 75, 21-30. 
[148] Miller, N.J.; Rice-Evans, C.A. Factors influencing the antioxidant 
activity determined by the ABTS.+ radical cation assay. Free 
Radic. Res., 1997, 26, 195-199. 
[149] Sharma, S.; Rakoczy, S.; Brown-Borg, H. Assessment of spatial 
memory in mice. Life Sci., 2010, 87, 521-536. 
[150] Luo, W.; Li, Y.P.; He, Y.; Huang, S.L.; Li, D.; Gu, L.Q.; Huang, 
Z.S. Synthesis and evaluation of heterobivalent tacrine derivatives 
as potential multi-functional anti-Alzheimer agents. Eur. J. Med. 
Chem., 2011, 46, 2609-2616. 
[151] Sul, D.; Kim, H.S.; Lee, D.; Joo, S.S.; Hwang, K.W.; Park, S.Y. 
Protective effect of caffeic acid against beta-amyloid-induced neu-
rotoxicity by the inhibition of calcium influx and tau phosphoryla-
tion. Life Sci., 2009, 84, 257-262. 
[152] Chao, X.; He, X.; Yang, Y.; Zhou, X.; Jin, M.; Liu, S.; Cheng, Z.; 
Liu, P.; Wang, Y.; Yu, J.; Tan, Y.; Huang, Y.; Qin, J.; Rapposelli, 
S.; Pi, R. Design, synthesis and pharmacological evaluation of 
novel tacrine-caffeic acid hybrids as multi-targeted compounds 
against Alzheimer's disease. Bioorg. Med. Chem. Lett., 2012, 22, 
6498-6502. 
[153] Zhao, R.; Holmgren, A. A novel antioxidant mechanism of ebselen 
involving ebselen diselenide, a substrate of mammalian thioredoxin 
and thioredoxin reductase. J. Biol. Chem., 2002, 277, 39456-39462. 
[154] Luo, Z.; Sheng, J.; Sun, Y.; Lu, C.; Yan, J.; Liu, A.; Luo, H.B.; 
Huang, L.; Li, X. Synthesis and evaluation of multi-target-directed 
ligands against Alzheimer's disease based on the fusion of donepe-
zil and ebselen. J. Med. Chem., 2013, 56, 9089-9099. 
[155] Wilson, S.R.; Zucker, P.A.; Huang, R.R.C.; Spector, A. Develop-
ment of synthetic compounds with glutathione peroxidase activity. 
J. Am. Chem. Soc., 1989, 111, 5936-5939. 
[156] Luo, Z.; Liang, L.; Sheng, J.; Pang, Y.; Li, J.; Huang, L.; Li, X. 
Synthesis and biological evaluation of a new series of ebselen de-
rivatives as glutathione peroxidase (GPx) mimics and cholinester-
ase inhibitors against Alzheimer’s disease. Bioorg. Med. Chem., 
2014, 22, 1355-1361. 
[157] Yanovsky, I.; Finkin-Groner, E.; Zaikin, A.; Lerman, L.; Shalom, 
H.; Zeeli, S.; Weill, T.; Ginsburg, I.; Nudelman, A.; Weinstock, M. 
Carbamate derivatives of indolines as cholinesterase inhibitors and 
antioxidants for the treatment of Alzheimer’s disease. J. Med. 
Chem., 2012, 55, 10700-10715. 
[158] Chyan, Y.J.; Poeggeler, B.; Omar, R.A.; Chain, D.G.; Frangione, 
B.; Ghiso, J.; Pappolla, M.A. Potent neuroprotective properties 
against the Alzheimer -amyloid by an endogenous melatonin-
related indole structure, indole-3-propionic acid. J. Biol. Chem., 
1999, 274, 21937-21942. 
[159] Ginsburg, I.; Sadovnic, M.; Oron, M.; Kohen, R. Novel chemilu-
minescence-inducing cocktails, part I: the role in light emission of 
combinations of luminal with SIN-1, selenite, albumin, glucose 
oxidase and Co2+. Inflammopharmacology, 2004, 12, 289-303. 
[160] Rosini, M.; Simoni, E.; Bartolini, M.; Tarozzi, A.; Matera, R.; 
Milelli, A.; Hrelia, P.; Andrisano, V.; Bolognesi, M.L.; Melchiorre, 
C. Exploiting the lipoic acid structure in the search for novel multi-
target ligands against Alzheimer’s disease. Eur. J. Med. Chem., 
2011, 46, 5435-5442. 
[161] Rosini, M.; Andrisano, V.; Bartolini, M.; Bolognesi, M.L.; Hrelia, 
P.; Minarini, A.; Tarozzi, A.; Melchiorre, C. Rational approach to 
discover multipotent anti-Alzheimer drugs. J. Med. Chem., 2005,
48, 360-363. 
[162] Chin, D.; Huebbe, P.; Pallauf, K.; Rimbach, G. Neuroprotective 
properties of curcumin in Alzheimer's disease - merits and limita-
tions. Curr. Med. Chem., 2013, 20, 3955-3985. 
[163] Park, S.; Kim, H.; Cho, E.; Kwon, B.; Phark, S.; Hwang, K.; Sul, 
D. Curcumin protected PC12 cells against beta-amyloid-induced 
toxicity through the inhibition of oxidative damage and tau hyper-
phosphorylation. Food Chem. Toxicol., 2008, 46, 2881-2887. 
[164] Thapa, A.; Vernon, B.C.; De la Peña, K.; Soliz, G.; Moreno, H.A.; 
López, G.P.; Chi, E.Y. Membrane-mediated neuroprotection by 
curcumin from amyloid--peptide-induced toxicity. Langmuir, 
2013, 29, 11713-11723. 
[165] Fang, L.; Gou, S.; Liu, X.; Cao, F.; Cheng, L. Design, synthesis 
and anti-Alzheimer properties of dimethylaminomethyl-substituted 
curcumin derivatives. Bioorg. Med. Chem. Lett., 2014, 24, 40-43. 
Recent Development of Multifunctional Agents Current Medicinal Chemistry, 2015, Vol. 22, No. 3    403
[166] Fang, X.; Fang, L.; Gou, S.; Cheng, L. Design and synthesis of 
dimethylaminomethyl-substituted curcumin derivatives/analogues: 
Potent antitumor and antioxidant activity, improved stability and 
aqueous solubility compared with curcumin. Bioorg. Med. Chem. 
Lett., 2013, 23, 1297-1301. 
[167] Bush, A.I.; Tanzi, R.E. Therapeutics for Alzheimer's disease based 
on the metal hypothesis. Neurotherapeutics, 2008, 5, 421-432. 
[168] Zhao, Y.; Zhao, B. Oxidative stress and the pathogenesis of Alz-
heimer's disease. Oxid. Med. Cell Longev., 2013, 2013, 316523. 
[169] Rivera-Mancía, S.; Pérez-Neri, I.; Ríos, C.; Tristán-López, L.; 
Rivera-Espinosa, L.; Montes, S. The transition metals copper and 
iron in neurodegenerative diseases. Chem. Biol. Interact., 2010,
186, 184-199. 
[170] Budimir, A. Metal ions, Alzheimer's disease and chelation therapy. 
Acta Pharm., 2011, 61, 1-14. 
[171] Li, X.; Jankovic, J.; Le, W. Iron chelation and neuroprotection in 
neurodegenerative diseases. J. Neural Transm., 2011, 118, 473-
477. 
[172] Li, R.; Wang, X.; Hu, X.; Kong, L. Design, synthesis and evalua-
tion of flavonoid derivatives as potential multifunctional acetylcho-
linesterase inhibitors against Alzheimer’s disease. Bioorg. Med. 
Chem. Lett., 2013, 23, 2636-2641. 
[173] Schroeter, H.; Spencer, J.; Rice-Evans, C.; Williams, R. Flavonoids 
protect neurons from oxidized low-density-lipoprotein-induced 
apoptosis involving c-Jun N-terminal kinase (JNK), c-Jun and 
caspase-3. Biochem. J., 2001, 358, 547-557. 
[174] Kim, H.; Park, B.; Lee, K.; Choi, C.Y.; Jang, S.S.; Kim, Y.; Lee, S. 
Effects of naturally occurring compounds on fibril formation and 
oxidative stress of -amyloid. J. Agric. Food Chem., 2005, 53, 
8537-8541. 
[175] Sugihara, N.; Arakawa, T.; Ohnishi, M.; Furuno, K. Anti- and pro-
oxidative effects of flavonoids on metal-induced lipid hydroperox-
ide-dependent lipid peroxidation in cultured hepatocytes loaded 
with alpha-linolenic acid. Free Radic. Biol. Med., 1999, 27, 1313-
1323. 
[176] Li, S.; Wang, X.; Xie, S.; Jiang, N.; Wang, K.D.; Yao, H.; Sun, H.; 
Kong, L. Multifunctional tacrine-flavonoid hybrids with choliner-
gic, -amyloid-reducing, and metal chelating properties for the 
treatment of Alzheimer's disease. Eur. J. Med. Chem., 2013, 69, 
632-646. 
[177] Xie, S.; Wang, X.; Li, J.; Yang, L.; Kong, L. Design, synthesis and 
evaluation of novel tacrine-coumarin hybrids as multifunctional 
cholinesterase inhibitors against Alzheimer's disease. Eur. J. Med. 
Chem., 2013, 64, 540-553. 
[178] Li, S.; Jiang, N.; Xie, S.; Wang, K.D.; Wang, X.; Kong, L. Design, 
synthesis and evaluation of novel tacrine-rhein hybrids as multi-
functional agents for the treatment of Alzheimer's disease. Org. 
Biomol. Chem., 2014, 12, 801-814. 
[179] Kryger, G.; Silman, I.; Sussman, J.L. Structure of acetylcho-
linesterase complexed with E2020 (Aricept): implications for the 
design of new anti-Alzheimer drugs. Structure, 1999, 7, 297-307. 
[180] Meng, F.; Mao, F.; Shan, W.; Qin, F.; Huang, L.; Li, X. Design, 
synthesis, and evaluation of indanone derivatives as acetylcho-
linesterase inhibitors and metal-chelating agents. Bioorg. Med. 
Chem. Lett., 2012, 22, 4462-4466. 
[181] Huang, L.; Lu, C.; Sun, Y.; Mao, F.; Luo, Z.; Su, T.; Jiang, H.; 
Shan, W.; Li, X. Multitarget-directed benzylideneindanone deriva-
tives: anti--amyloid (A) aggregation, antioxidant, metal chela-
tion, and monoamine oxidase B (MAO-B) inhibition properties 
against Alzheimer’s disease. J. Med. Chem., 2012, 55, 8483-8492. 
[182] He, Y.; Yao, P.; Chen, S.; Huang, Z.; Huang, S.; Tan, J.; Li, D.; 
Gu, L.; Huang, Z. Synthesis and evaluation of 7, 8-
dehydrorutaecarpine derivatives as potential multifunctional agents 
for the treatment of Alzheimer's disease. Eur. J. Med. Chem. 2013,
63, 299-312. 
[183] Wang, B.; Mai, Y.; Li, Y.; Hou, J.; Huang, S.; Ou, T.; Tan, J.; An, 
L.; Li, D.; Gu, L. Synthesis and evaluation of novel rutaecarpine 
derivatives and related alkaloids derivatives as selective acetylcho-
linesterase inhibitors. Eur. J. Med. Chem., 2010, 45, 1415-1423. 
[184] Yang, W.; Wong, Y.; Ng, O.T.; Bai, L.; Kwong, D.W.; Ke, Y.; 
Jiang, Z.; Li, H.; Yung, K.K.; Wong, M.S. Inhibition of 
BetaAmyloid Peptide Aggregation by Multifunctional Carba-
zoleBased Fluorophores. Angew. Chem. Int. Ed. Engl., 2012, 51, 
1804-1810. 
[185] Richard, T.; Pawlus, A.D.; Iglésias, M.; Pedrot, E.; WaffoTeguo, 
P.; Mérillon, J.; Monti, J. Neuroprotective properties of resveratrol 
and derivatives. Ann. N. Y. Acad. Sci., 2011, 1215, 103-108. 
[186] Baur, J.A.; Sinclair, D.A. Therapeutic potential of resveratrol: the 
in vivo evidence. Nat. Rev. Drug Discov., 2006, 5, 493-506. 
[187] Yao, R.; Lu, X.; Guan, Q.; Zheng, L.; Lu, X.; Ruan, B. Synthesis 
and biological evaluation of some novel resveratrol amide deriva-
tives as potential anti-tumor agents. Eur. J. Med. Chem,. 2013, 62, 
222-231. 
[188] Sharma, M.; Gupta, Y. Chronic treatment with trans resveratrol 
prevents intracerebroventricular streptozotocin induced cognitive 
impairment and oxidative stress in rats. Life Sci., 2002, 71, 2489-
2498. 
[189] Jang, J.; Surh, Y. Protective effect of resveratrol on -amyloid-
induced oxidative PC12 cell death. Free Radic. Biol. Med., 2003,
34, 1100-1110. 
[190] Lu, C.; Guo, Y.; Li, J.; Yao, M.; Liao, Q.; Xie, Z.; Li, X. Design, 
synthesis, and evaluation of resveratrol derivatives as A1-42 aggre-
gation inhibitors, antioxidants, and neuroprotective agents. Bioorg. 
Med. Chem. Lett., 2012, 22, 7683-7687. 
[191] Lu, C.; Guo, Y.; Yan, J.; Luo, Z.; Luo, H.; Yan, M.; Huang, L.; Li, 
X. Design, synthesis, and evaluation of multitarget-directed res-
veratrol derivatives for the treatment of Alzheimer’s disease. J. 
Med. Chem., 2013, 56, 5843-5859. 
[192] Li, S.; Wang, X.; Kong, L. Design, synthesis and biological evalua-
tion of imine resveratrol derivatives as multi-targeted agents 
against Alzheimer's disease. Eur. J. Med. Chem., 2014, 71, 36-45. 
[193] Cooke, J.P.; Dzau, V.J. Nitric oxide synthase: role in the genesis of 
vascular disease. Annu. Rev. Med., 1997, 48, 489-509. 
[194] Faraci, F.M. Role of endothelium-derived relaxing factor in cere-
bral circulation: large arteries vs. microcirculation. Am. J. Physiol., 
1991, 261, H1038-H1042. 
[195] Fang, L.; Kraus, B.; Lehmann, J.; Heilmann, J.; Zhang, Y.; Decker, 
M. Design and synthesis of tacrine-ferulic acid hybrids as multi-
potent anti-Alzheimer drug candidates. Bioorg. Med. Chem. Lett., 
2008, 18, 2905-2909. 
[196] Fang, L.; Appenroth, D.; Decker, M.; Kiehntopf, M.; Roegler, C.; 
Deufel, T.; Fleck, C.; Peng, S.; Zhang, Y.; Lehmann, J. Synthesis 
and biological evaluation of NO-donor-tacrine hybrids as hepato-
protective anti-Alzheimer drug candidates. J. Med. Chem., 2008,
51, 713-716. 
[197] Fang, L.; Appenroth, D.; Decker, M.; Kiehntopf, M.; Lupp, A.; 
Peng, S.; Fleck, C.; Zhang, Y.; Lehmann, J. NO-donating tacrine 
hybrid compounds improve scopolamine-induced cognition im-
pairment and show less hepatotoxicity. J. Med. Chem., 2008, 51, 
7666-7669. 
[198] Chen, Y.; Sun, J.; Fang, L.; Liu, M.; Peng, S.; Liao, H.; Lehmann, 
J.; Zhang, Y. Tacrine-ferulic acid-nitric oxide (NO) donor trihy-
brids as potent, multifunctional acetyl-and butyrylcholinesterase 
inhibitors. J. Med. Chem., 2012, 55, 4309-4321. 
[199] Sorba, G.; Medana, C.; Fruttero, R.; Cena, C.; Di Stilo, A.; Galli, 
U.; Gasco, A. Water soluble furoxan derivatives as NO prodrugs. J. 
Med. Chem., 1997, 40, 463-469. 
[200] Chen, Y.; Sun, J.; Huang, Z.; Liao, H.; Peng, S.; Lehmann, J.; 
Zhang, Y. NO-donating tacrine derivatives as potential butyrylcho-
linesterase inhibitors with vasorelaxation activity. Bioorg. Med. 
Chem. Lett., 2013, 23, 3162-3165. 
[201] Chen, Y.; Sun, J.; Huang, Z.; Liao, H.; Peng, S.; Lehmann, J.; 
Zhang, Y. Design, synthesis and evaluation of tacrine-flurbiprofen-
nitrate trihybrids as novel anti-Alzheimer’s disease agents. Bioorg. 
Med. Chem., 2013, 21, 2462-2470. 
[202] Chen, Y.; Sun, J.; Peng, S.; Liao, H.; Zhang, Y.; Lehmann, J. 
Tacrine-flurbiprofen hybrids as multifunctional drug candidates for 
the treatment of Alzheimer's disease. Arch. Pharm. (Weinheim), 
2013, 346, 865-871. 
[203] Fang, L.; Fang, X.; Gou, S.; Lupp, A.; Lenhardt, I.; Sun, Y.; 
Huang, Z.; Chen, Y.; Zhang, Y.; Fleck, C. Design, synthesis and 
biological evaluation of D-ring opened galantamine analogs as 
multifunctional anti-Alzheimer agents. Eur. J. Med. Chem., 2014,
76, 376-386. 
[204] Greenblatt, H.; Kryger, G.; Lewis, T.; Silman, I.; Sussman, J. 
Structure of acetylcholinesterase complexed with ()-galanthamine 
at 2.3 Å resolution. FEBS Lett., 1999, 463, 321-326. 
[205] Zhang, W.; Ruan, J.; Wu, P.; Jiang, F.; Zhang, L.N.; Fang, W.; 
Chen, X.; Wang, Y.; Cao, B.; Chen, G. Design, synthesis, and cy-
toprotective effect of 2-aminothiazole analogues as potent poly 
(ADP-ribose) polymerase-1 inhibitors. J. Med. Chem., 2009, 52, 
718-725. 
[206] Wang, Y.; Wang, F.; Yu, J.P.; Jiang, F.C.; Guan, X.L.; Wang, 
C.M.; Li, L.; Cao, H.; Li, M.X.; Chen, J.G. Novel multipotent 
phenylthiazole-tacrine hybrids for the inhibition of cholinesterase 
activity, -amyloid aggregation and Ca2+ overload. Bioorg. Med. 
Chem., 2012, 20, 6513-6522. 
[207] González-Muñoz, G.C.; Arce, M.P.; López, B.; Pérez, C.; Romero, 
A.; del Barrio, L.; Martín-de-Saavedra, M.D.; Egea, J.; León, R.; 
404    Current Medicinal Chemistry, 2015, Vol. 22, No. 3 Guzior et al. 
Villarroya, M.; López, M.G.; García, A.G.; Conde, S.; Rodríguez-
Franco, M.I. N-Acylaminophenothiazines: Neuroprotective agents 
displaying multifunctional activities for a potential treatment of 
Alzheimer’s disease. Eur. J. Med. Chem., 2011, 46, 2224-2235. 
[208] Zhang, Z.; Simpkins, J.W. An okadaic acid-induced model of 
tauopathy and cognitive deficiency. Brain Res., 2010, 1359, 233-
246. 
[209] Minarini, A.; Milelli, A.; Tumiatti, V.; Rosini, M.; Simoni, E.; 
Bolognesi, M.; Andrisano, V.; Bartolini, M.; Motori, E.; Angeloni, 
C. Cystamine-tacrine dimer: a new multi-target-directed ligand as 
potential therapeutic agent for Alzheimer’s disease treatment. Neu-
ropharmacology, 2012, 62, 997-1003. 
[210] Wood, P.L.; Khan, M.A.; Moskal, J.R. Cellular thiol pools are 
responsible for sequestration of cytotoxic reactive aldehydes: cen-
tral role of free cysteine and cysteamine. Brain Res., 2007, 1158, 
158-163. 
[211] Simoni, E.; Daniele, S.; Bottegoni, G.; Pizzirani, D.; Trincavelli, 
M.L.; Goldoni, L.; Tarozzo, G.; Reggiani, A.; Martini, C.; Piomelli, 
D. Combining galantamine and memantine in multitargeted, new 
chemical entities potentially useful in Alzheimer’s disease. J. Med. 
Chem., 2012, 55, 9708-9721. 
[212] Rosini, M.; Simoni, E.; Bartolini, M.; Soriano, E.; 
MarcoContelles, J.; Andrisano, V.; Monti, B.; Windisch, M.; Hut-
terPaier, B.; McClymont, D.W. The bivalent ligand approach as a 
tool for improving the in vitro antiAlzheimer multitarget profile of 
dimebon. ChemMedChem, 2013, 8, 1276-1281. 
[213] Bachurin, S.; Bukatina, E.; Lermontova, N.; Tkachenko, S.; Afana-
siev, A.; Grigoriev, V.; Grigorieva, I.; Ivanov, Y.; Sablin, S.; Zefi-
rov, N. Antihistamine agent Dimebon as a novel neuroprotector 
and a cognition enhancer. Ann. N. Y. Acad. Sci., 2001, 939, 425-
435. 
[214] Hartbauer, M.; Hutter-Paier, B.; Windisch, M. Effects of Cerebro-
lysin on the outgrowth and protection of processes of cultured brain 
neurons. J. Neural Transm., 2001, 108, 581-592. 
[215] Bisogno, T.; Di Marzo, V. The role of the endocannabinoid system 
in Alzheimer's disease: facts and hypotheses. Curr. Pharm. Des., 
2008, 14, 2299-2305. 
[216] Gowran, A.; Noonan, J.; Campbell, V.A. The multiplicity of action 
of cannabinoids: implications for treating neurodegeneration. CNS 
Neurosci. Ther., 2011, 17, 637-644. 
[217] Rizzo, S.; Tarozzi, A.; Bartolini, M.; Da Costa, G.; Bisi, A.; Gobbi, 
S.; Belluti, F.; Ligresti, A.; Allarà, M.; Monti, J. 2-Arylbenzofuran-
based molecules as multipotent Alzheimer's disease modifying 
agents. Eur. J. Med. Chem., 2012, 58, 519-532. 
[218] González-Naranjo, P.; Pérez-Macias, N.; Campillo, N.E.; Pérez, C.; 
Arán, V.J.; Girón, R.; Sánchez-Robles, E.; Martín, M.I.; Gómez-
Cañas, M.; García-Arencibia, M. Cannabinoid agonists showing 
BuChE inhibition as potential therapeutic agents for Alzheimer's 
disease. Eur. J. Med. Chem., 2014, 73, 56-72. 
[219] Berlin, M.; Boyce, C.W.; de Lera Ruiz, M. Histamine H3 receptor 
as a drug discovery target. J. Med. Chem., 2011, 54, 26-53. 
[220] Gemkow, M.J.; Davenport, A.J.; Harich, S.; Ellenbroek, B.A.; 
Cesura, A.; Hallett, D. The histamine H3 receptor as a therapeutic 
drug target for CNS disorders. Drug Discov. Today, 2009, 14, 509-
515. 
[221] Singh, M.R.; Jadhav, H. Histamine H3 receptor function and 
ligands: recent developments. Mini Rev. Med. Chem., 2013, 13, 47-
57. 
[222] aewska, D.; Kie-Kononowicz, K. Recent advances in histamine 
H3 receptor antagonists/inverse agonists. Expert Opin. Ther. Pat., 
2010, 20, 1147-1169. 
[223] Petroianu, G.; Arafat, K.; Sasse, B.; Stark, H. Multiple enzyme 
inhibitions by histamine H3 receptor antagonists as potential pro-
cognitive agents. Pharmazie, 2006, 61, 179-182. 
[224] Esbenshade, T.A.; Fox, G.B.; Cowart, M.D. Histamine H3 receptor 
antagonists: preclinical promise for treating obesity and cognitive 
disorders. Mol. Interv., 2006, 6, 77-88, 59. 
[225] Bajda, M.; Kuder, K.J.; aewska, D.; KieKononowicz, K.; 
Wickowska, A.; Ignasik, M.; Guzior, N.; Joczyk, J.; Malawska, 
B. Dualacting diether derivatives of piperidine and ho-
mopiperidine with histamine H3 receptor antagonistic and anticho-
linesterase activity. Arch. Pharm. (Weinheim), 2012, 345, 591-597. 
[226] Darras, F.H.; Pockes, S.; Huang, G.; Wehle, S.; Strasser, A.; Witt-
mann, H.; Nimczick, M.; Sotriffer, C.A.; Decker, M. Synthesis, 
biological evaluation, and computational studies of tri-and tetra-
cyclic nitrogen-bridgehead compounds as potent dual-acting AChE 
inhibitors and hH3 receptor antagonists. ACS Chem. Neurosci., 
2014, 5, 225-242. 
[227] Darras, F.H.; Kling, B.; Heilmann, J.; Decker, M. Neuroprotective 
tri-and tetracyclic BChE inhibitors releasing reversible inhibitors 
upon carbamate transfer. ACS Med. Chem. Lett., 2012, 3, 914-919. 
[228] Puccio, S.; Chu, J.; Pratico, D. Involvement of 5-lipoxygenase in 
the corticosteroid-dependent amyloid beta formation: in vitro and 
in vivo evidence. PloS One, 2011, 6, e15163. 
[229] Chu, J.; Praticò, D. Pharmacologic Blockade of 5-Lipoxygenase 
Improves the Amyloidotic Phenotype of an Alzheimer's Disease 
Transgenic Mouse Model: Involvement of -Secretase. Am. J. 
Pathol., 2011, 178, 1762-1769. 
[230] Firuzi, O.; Zhuo, J.; Chinnici, C.M.; Wisniewski, T.; Pratico, D. 5-
Lipoxygenase gene disruption reduces amyloid- pathology in a 
mouse model of Alzheimer's disease. FASEB J., 2008, 22, 1169-
1178. 
[231] Chen, Y.P.; Zhang, Z.Y.; Li, Y.P.; Li, D.; Huang, S.L.; Gu, L.Q.; 
Xu, J.; Huang, Z.S. Syntheses and evaluation of novel isoliquiriti-
genin derivatives as potential dual inhibitors for amyloid-beta ag-
gregation and 5-lipoxygenase. Eur. J. Med. Chem., 2013, 66, 22-
31. 
[232] Cummings, J.L.; Morstorf, T.; Zhong, K. Alzheimer's disease drug-
development pipeline: few candidates, frequent failures. Alzheimers 
Res. Ther., 2014, 6, 37.
Received: June 09, 2014 Revised: September 29, 2014    Accepted: October 30, 2014 
